HTG Molecular Diagnostics (HTGMQ) 10-Q 10 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 06, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	0001169987
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		71,096,029
Entity File Number	001-37369
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-0912294
Entity Address, Address Line One	3430 E. Global Loop
Entity Address, City or Town	Tucson
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85706
City Area Code	(877)
Local Phone Number	289-2615
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 18,884,468	$ 7,619,748
Short-term investments available-for-sale, at fair value	11,632,160	25,410,222
Restricted cash		3,270,247
Accounts receivable	1,370,201	3,164,176
Inventory, net of allowance of $27,770 at September 30, 2020 and $39,403 at December 31, 2019	1,538,553	1,269,667
Prepaid expenses and other	946,979	633,522
Total current assets	34,372,361	41,367,582
Operating lease right-of-use assets	746,185	1,209,145
Property and equipment, net	1,526,698	2,240,133
Other non-current assets	64,861	302,409
Total assets	36,710,105	45,119,269
Current liabilities:
Accounts payable	875,236	1,662,583
Accrued liabilities	1,386,825	1,870,296
Contract liabilities - current	348,274	426,014
NuvoGen obligation - current	645,949	1,152,233
Current portion of long-term debt, net	2,266,884	2,987,667
Operating lease liabilities - current	436,663	758,932
Other current liabilities	26,620	41,134
Total current liabilities	5,986,451	8,898,859
NuvoGen obligation - non-current, net of discount	4,455,968	4,498,777
Long-term debt, net of current portion and discount and debt issuance costs	9,446,985	6,871,545
Operating lease liabilities - non-current	390,233	636,340
Other non-current liabilities	229,114	244,114
Total liabilities	20,508,751	21,149,635
Commitments and Contingencies (Note 15)
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 23,770 shares authorized at September 30, 2020 and no shares authorized at December 31, 2019; 23,770 shares issued and outstanding at September 30, 2020 and no shares issued and outstanding at December 31, 2019	24
Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2020 and December 31, 2019, 71,078,958 shares issued and outstanding at September 30, 2020 and 58,090,233 shares issued and outstanding at December 31, 2019	71,079	58,090
Additional paid-in-capital	203,021,404	194,234,151
Accumulated other comprehensive income (loss)	6,727	(4,964)
Accumulated deficit	(186,897,880)	(170,317,643)
Total stockholders’ equity	16,201,354	23,969,634
Total liabilities and stockholders' equity	$ 36,710,105	$ 45,119,269

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Inventory net allowance	$ 27,770	$ 39,403
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	71,078,958	58,090,233
Common stock, shares outstanding	71,078,958	58,090,233
Series A Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	23,770	0
Preferred stock, shares issued	23,770	0
Preferred stock, shares outstanding	23,770	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Total revenue	$ 1,777,098	$ 5,404,793	$ 5,965,866	$ 14,403,938
Operating expenses:
Cost of product and product-related services revenue	$ 940,892	$ 2,939,007	$ 2,931,026	$ 7,492,905
Type of Cost, Good or Service [Extensible List]	htgm:ProductAndProductRelatedServicesMember	htgm:ProductAndProductRelatedServicesMember	htgm:ProductAndProductRelatedServicesMember	htgm:ProductAndProductRelatedServicesMember
Selling, general and administrative	$ 4,752,321	$ 4,516,341	$ 13,683,069	$ 13,657,917
Research and development	1,255,416	2,570,355	4,914,467	7,898,742
Total operating expenses	6,948,629	10,025,703	21,528,562	29,049,564
Operating loss	(5,171,531)	(4,620,910)	(15,562,696)	(14,645,626)
Other income (expense):
Interest expense	(273,312)	(241,860)	(749,401)	(714,623)
Interest income	34,636	118,860	244,534	455,071
Other income			22,268
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note			(522,394)
Total other expense	(238,676)	(123,000)	(1,004,993)	(259,552)
Net loss before income taxes	(5,410,207)	(4,743,910)	(16,567,689)	(14,905,178)
Benefit from (provision for) income taxes	(1,581)	3,678	(12,548)	(3,170)
Net loss	$ (5,411,788)	$ (4,740,232)	$ (16,580,237)	$ (14,908,348)
Net loss per share, basic and diluted	$ (0.07)	$ (0.15)	$ (0.25)	$ (0.50)
Shares used in computing net loss per share, basic and diluted	72,323,436	31,367,044	67,567,031	29,551,836
Product and Product-related Services
Revenue:
Total revenue	$ 1,701,068	$ 4,311,043	$ 5,417,731	$ 11,397,916
Collaborative Development Services
Revenue:
Total revenue	$ 76,030	$ 1,093,750	$ 548,135	$ 3,006,022

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (5,411,788)	$ (4,740,232)	$ (16,580,237)	$ (14,908,348)
Other comprehensive income (loss), net of tax effect:
Unrealized gain (loss) on short-term investments	(17,501)	(1,864)	4,060	2,308
Foreign currency translation adjustment	1,225	37,575	7,631	34,820
Total other comprehensive income (loss)	(16,276)	35,711	11,691	37,128
Comprehensive loss	$ (5,428,064)	$ (4,704,521)	$ (16,568,546)	$ (14,871,220)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	LP Purchase Agreement	ATM Offering	Private Placement	Series A Convertible Preferred Stock	Series A Convertible Preferred StockPrivate Placement	Common Stock	Common StockLP Purchase Agreement	Common StockATM Offering	Additional Paid-In Capital	Additional Paid-In CapitalLP Purchase Agreement	Additional Paid-In CapitalATM Offering	Additional Paid-In CapitalPrivate Placement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2018	$ 21,092,062						$ 28,585			$ 172,086,909				$ (3,453)	$ (151,019,979)
Balance, shares at Dec. 31, 2018							28,585,449
Exercise of stock options	51,570						$ 22			51,548
Exercise of stock options, shares							21,871
Stock-based compensation expense	241,233									241,233
Release of restricted stock awards	13						$ 13
Release of restricted stock awards, shares							13,126
Net share settlement of restricted stock award	(9,685)						$ (4)			(9,681)
Net share settlement of restricted stock award, shares							(3,813)
Employee stock purchase plan expense	16,794									16,794
Net loss	(5,370,846)														(5,370,846)
Unrealized gain (loss) on short-term investments	3,353													3,353
Foreign currency translation adjustment	6,439													6,439
Balance at Mar. 31, 2019	16,030,933						$ 28,616			172,386,803				6,339	(156,390,825)
Balance, shares at Mar. 31, 2019							28,616,633
Balance at Dec. 31, 2018	21,092,062						$ 28,585			172,086,909				(3,453)	(151,019,979)
Balance, shares at Dec. 31, 2018							28,585,449
Net loss	(14,908,348)
Unrealized gain (loss) on short-term investments	2,308
Balance at Sep. 30, 2019	28,116,504						$ 58,031			193,953,125				33,675	(165,928,327)
Balance, shares at Sep. 30, 2019							58,031,230
Balance at Mar. 31, 2019	16,030,933						$ 28,616			172,386,803				6,339	(156,390,825)
Balance, shares at Mar. 31, 2019							28,616,633
Exercise of stock options	69,384						$ 32			69,352
Exercise of stock options, shares							32,385
Stock-based compensation expense	287,317									287,317
Release of restricted stock awards	15						$ 15
Release of restricted stock awards, shares							15,001
Net share settlement of restricted stock award	(11,152)						$ (4)			(11,148)
Net share settlement of restricted stock award, shares							(4,461)
Stock issued under stock purchase plans	99,140						$ 48			99,092
Stock issued under stock purchase plans, shares							47,489
Net loss	(4,797,270)														(4,797,270)
Unrealized gain (loss) on short-term investments	819													819
Foreign currency translation adjustment	(9,194)													(9,194)
Balance at Jun. 30, 2019	11,669,992						$ 28,707			172,831,416				(2,036)	(161,188,095)
Balance, shares at Jun. 30, 2019							28,707,047
Stock-based compensation expense	316,525									316,525
Release of restricted stock awards	30						$ 30
Release of restricted stock awards, shares							30,001
Net share settlement of restricted stock award	(7,230)						$ (5)			(7,225)
Net share settlement of restricted stock award, shares							(4,355)
Employee stock purchase plan expense	16,325									16,325
Issuance of common stock and warrants from the public and private offerings, net of issuance costs	20,825,383						$ 29,299			20,796,084
Issuance of common stock and warrants from the public and private offerings, net of issuance costs, shares							29,298,537
Net loss	(4,740,232)														(4,740,232)
Unrealized gain (loss) on short-term investments	(1,864)													(1,864)
Foreign currency translation adjustment	37,575													37,575
Balance at Sep. 30, 2019	28,116,504						$ 58,031			193,953,125				33,675	(165,928,327)
Balance, shares at Sep. 30, 2019							58,031,230
Balance at Dec. 31, 2019	23,969,634						$ 58,090			194,234,151				(4,964)	(170,317,643)
Balance, shares at Dec. 31, 2019							58,090,233
Stock-based compensation expense	415,256									415,256
Release of restricted stock awards	36						$ 36
Release of restricted stock awards, shares							35,942
Net share settlement of restricted stock award	(7,052)						$ (11)			(7,041)
Net share settlement of restricted stock award, shares							(11,266)
Employee stock purchase plan expense	5,379									5,379
Issuance of common stock			$ 2,435,912					$ 615	$ 4,399		$ (615)	$ 2,431,513
Issuance of common stock, shares								615,384	4,399,062
Issuance of preferred stock	2,424,900			$ 562,955	$ 41	$ 10				2,424,859			$ 562,945
Issuance of preferred stock, shares					41,100	10,170
Cancellation of common stock received in exchange for Series A convertible preferred stock	(2,424,900)						$ (4,110)			(2,420,790)
Cancellation of common stock received in exchange for Series A convertible preferred stock, shares							(4,110,000)
Exercise of pre-funded warrants	31,768						$ 3,177			28,591
Exercise of pre-funded warrants, shares							3,176,762
Adjustment in connection with LP Purchase Agreement commitment fee and transaction costs		$ (96,000)									(96,000)
Net loss	(5,457,898)														(5,457,898)
Unrealized gain (loss) on short-term investments	47,697													47,697
Foreign currency translation adjustment	5,497													5,497
Balance at Mar. 31, 2020	21,913,184				$ 51		$ 62,196			197,578,248				48,230	(175,775,541)
Balance, shares at Mar. 31, 2020					51,270		62,196,117
Balance at Dec. 31, 2019	23,969,634						$ 58,090			194,234,151				(4,964)	(170,317,643)
Balance, shares at Dec. 31, 2019							58,090,233
Issuance of common stock, shares									10,436,016
Net loss	(16,580,237)
Unrealized gain (loss) on short-term investments	4,060
Balance at Sep. 30, 2020	16,201,354				$ 24		$ 71,079			203,021,404				6,727	(186,897,880)
Balance, shares at Sep. 30, 2020					23,770		71,078,958
Balance at Mar. 31, 2020	21,913,184				$ 51		$ 62,196			197,578,248				48,230	(175,775,541)
Balance, shares at Mar. 31, 2020					51,270		62,196,117
Stock-based compensation expense	361,477									361,477
Release of restricted stock awards	24						$ 24
Release of restricted stock awards, shares							23,751
Net share settlement of restricted stock award	(2,108)						$ (7)			(2,101)
Net share settlement of restricted stock award, shares							(6,389)
Stock issued under stock purchase plans	30,512						$ 45			30,467
Stock issued under stock purchase plans, shares							45,490
Issuance of common stock			1,395,058						$ 2,085			1,392,973
Issuance of common stock, shares									2,084,714
Conversion of Series A convertible preferred stock for common stock					$ (27)		$ 2,750			(2,723)
Conversion of Series A convertible preferred stock for common stock, shares					(27,500)		2,750,000
Adjustment in connection with LP Purchase Agreement commitment fee and transaction costs		$ 301,538									$ 301,538
Issuance of common stock warrants in connection with SVB Term Loan	420,000									420,000
Net loss	(5,710,551)														(5,710,551)
Unrealized gain (loss) on short-term investments	(26,136)													(26,136)
Foreign currency translation adjustment	909													909
Balance at Jun. 30, 2020	18,683,907				$ 24		$ 67,093			200,079,879				23,003	(181,486,092)
Balance, shares at Jun. 30, 2020					23,770		67,093,683
Stock-based compensation expense	386,911									386,911
Release of restricted stock awards	38						$ 38
Release of restricted stock awards, shares							38,126
Net share settlement of restricted stock award	(3,664)						$ (4)			(3,660)
Net share settlement of restricted stock award, shares							(5,091)
Employee stock purchase plan expense	5,214									5,214
Issuance of common stock			$ 2,557,012						$ 3,952			$ 2,553,060
Issuance of common stock, shares									3,952,240
Net loss	(5,411,788)														(5,411,788)
Unrealized gain (loss) on short-term investments	(17,501)													(17,501)
Foreign currency translation adjustment	1,225													1,225
Balance at Sep. 30, 2020	$ 16,201,354				$ 24		$ 71,079			$ 203,021,404				$ 6,727	$ (186,897,880)
Balance, shares at Sep. 30, 2020					23,770		71,078,958

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019
Statement Of Stockholders Equity [Abstract]
At the market offering, commissions and issuance costs	$ 79,000	$ 43,000	$ 174,000
Private placement issuance costs			$ 37,075
Public and private offering issuance costs				$ 1,700,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net loss	$ (16,580,237)	$ (14,908,348)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,039,989	920,863
Accretion of discount on NuvoGen obligation	(9,771)	(10,273)
Provision for excess inventory	5,649	126,582
Write-off of Cowen ATM offering costs		108,883
Amortization of QNAH Convertible Note issuance costs	6,505	10,091
Amortization of MidCap Credit Facility discount and issuance costs	101,482	128,476
Amortization of SVB Term Loan discount and issuance costs	121,168
Stock-based compensation expense	1,163,742	845,133
Employee stock purchase plan expense	15,972	49,914
Non-cash operating lease expense	465,504	329,248
Accrued interest on available-for-sale securities investments	(101,996)	(231,272)
Issuance of common stock in connection with LP Purchase Agreement	205,538
Loss on extinguishment of Midcap Credit Facility and QNAH Convertible Note	522,394
Loss on abandonment and disposal of assets, net	77,498
Changes in operating assets and liabilities:
Accounts receivable	1,793,975	1,079,317
Inventory	(255,718)	(11,715)
Prepaid expenses and other	457,504	(383,643)
Deferred offering costs	140,320
Accounts payable	(778,706)	928,454
Accrued liabilities	(474,521)	(1,526,835)
Contract liabilities	(74,700)	152,681
Operating lease liabilities	(583,828)	(446,403)
Net cash used in operating activities	(12,742,237)	(12,838,847)
Investing activities
Purchase of property and equipment	(418,712)	(753,430)
Maturities of available-for-sale securities	25,450,000	30,800,000
Purchase of available-for-sale securities	(11,565,882)	(10,922,764)
Net cash provided by investing activities	13,465,406	19,123,806
Financing activities
Proceeds from issuance of SVB Term Loan and common stock warrants	10,000,000
Payment of SVB Term Loan issuance costs	(115,193)
Proceeds from 2019 underwritten public and private offerings, net of underwriting discounts, commissions and costs of $1.7 million		21,102,077
Proceeds from ATM Offering, net	6,387,982
Proceeds from PPP Loan	1,717,000
Proceeds from Series A convertible preferred stock in private placement	562,955
Payments on NuvoGen obligation	(539,323)	(1,003,634)
Proceeds from exercise of pre-funded warrants	31,768
Proceeds from shares purchased under stock purchase plans	25,133	82,345
Proceeds from exercise of stock options		120,954
Payments on financing leases	(32,553)	(34,928)
Taxes paid for net share settlement of restricted stock awards	(12,824)	(28,067)
Payment of deferred offering costs		(139,058)
Payments on Insurance Note	(324,301)
Net cash provided by financing activities	7,262,021	20,099,689
Effect of exchange rates on cash	9,283	29,838
Increase in cash, cash equivalents and restricted cash	7,994,473	26,414,486
Cash, cash equivalents and restricted cash at beginning of period	10,889,995	11,702,847
Cash, cash equivalents and restricted cash at end of period	18,884,468	38,117,333
Supplemental disclosure of noncash investing and financing activities
Issuance of Series A convertible preferred stock in exchange for outstanding common stock	2,424,900
Issuance of Common stock in exchange for Series A convertible preferred stock	1,622,500
Adoption of ASC 842, Leases		694,352
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	21,078	1,005,085
Carrying value of demonstration units transferred from property and equipment to inventory	18,817
Fixed asset purchases payable and accrued at period end		21,381
Offering costs payable and accrued at period end		276,694
Supplemental cash flow information
Cash paid for interest	719,676	521,538
Cash paid for taxes	9,961	$ 3,170
QNAH Convertible Note
Financing activities
Payments for extinguishment of debt	(3,000,000)
MidCap Credit Facility
Financing activities
Payments for extinguishment of debt	$ (7,438,623)

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Parenthetical) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
2019 Underwritten Public and Private Offerings
Underwriting discounts, commissions and issuance costs	$ 1.7

Description of Business, Basis

Description of Business, Basis of Presentation and Principles of Consolidation	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Description of Business, Basis of Presentation and Principles of Consolidation	Note 1. Description of Business, Basis of Presentation and Principles of Consolidation HTG Molecular Diagnostics, Inc. (the “Company”) is a provider of instruments, reagents and services for molecular profiling applications. The Company derives revenue from sales of its HTG EdgeSeq instrument system and integrated next-generation sequencing-based (“NGS-based”) HTG EdgeSeq assays, from services including sample processing and custom research use only (“RUO”) assay design and from collaborative development services. The Company operates in one segment and its customers are located primarily in the United States and Europe. For the three and nine months ended September 30, 2020 19% and 31%, respectively, of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with 29% and 31% for the three and nine months ended September 30, 2019, respectively. COVID-19 Pandemic On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (“COVID-19”) originating in Wuhan, China and the risks to the international community as the virus spreads globally. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. The full impact of the COVID-19 pandemic continues to evolve as of the date of this report and likewise the full impact of the pandemic on the Company’s financial condition, liquidity and future results of operations is uncertain. Management is actively monitoring the potential impact of the global situation on its financial condition, liquidity, operations, suppliers, industry and workforce. Given the daily evolution of the COVID-19 pandemic and the global responses to curb its spread, the Company is not able to fully estimate the effects of the COVID-19 pandemic on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and believes this period of reduced revenue will continue through at least the remainder of 2020 due to disruptions to its customers’ businesses as a result of the pandemic. The extent of this impact varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic. The Company has experienced very limited delays in its development efforts as a result of stay-at-home orders despite its efforts to prioritize the safety of its employees during this pandemic. The Company believes the COVID-19 pandemic will continue to impact its productivity, supply chains, distribution networks and other areas of its operation as ongoing concerns regarding the pandemic continue to disrupt the Company’s business and the businesses of its vendors, partners and customers . Although the Company cannot estimate the length and gravity of the impact of the COVID-19 pandemic at this time, the COVID-19 pandemic is expected to have a continuing adverse effect on the Company’s results of operations, financial position and liquidity for at least the remainder of 2020. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the COVID-19 pandemic. On April 21, 2020, the Company received proceeds from a loan in the amount of $1,717,000 from SVB, as lender, pursuant to the Paycheck Protection Program of the CARES Act (the “PPP loan”) (see Note 8). While there remains uncertainty as to the ultimate impact of the COVID-19 pandemic, the Company has considered the known impacts on its business as of the date of this report and has reflected any known or expected impacts in its accompanying condensed consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“U.S. GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The accompanying condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and disclosures required by U.S. GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2020. Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year of the filing of this Quarterly Report on Form 10-Q with the SEC. The accompanying interim unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of the assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $186.9 million as of September 30, 2020. As of September 30, 2020, the Company had working capital of $28.4 million and long-term liabilities of $14.5 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured Loan and Security Agreement with Silicon Valley Bank (the “SVB Term Loan”), the PPP Loan, and a commercial financing agreement extending the payment period related to its director and officer insurance policy The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant requiring the Company to maintain a certain amount of unrestricted cash under its SVB Term Loan. Principles of Consolidation The Company formed a French subsidiary, HTG Molecular Diagnostics France SARL (“HTG France”), in November 2018. The accompanying condensed consolidated financial statements include the accounts of the Company and this wholly-owned subsidiary after elimination of all intercompany transactions and balances as of September 30, 2020 and December 31, 2019. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents, available-for-sale debt securities and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The available-for-sale debt securities are comprised primarily of investments in U.S. Treasury and high-quality debt securities. The Company sells its instrument, related consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top two customers accounted for 24% and 10% of the Company’s total revenue for the three months ended September 30, 2020, compared with the Company’s top two customers accounting for 39% and 20% of the Company’s total revenue for the three months ended September 30, 2019. The Company’s top two customers accounted for 16% and 10% of the Company’s total revenue for the nine months ended September 30, 2020 compared with the Company’s top three customers accounting for 23%, 22% and 21% for the nine months ended September 30, 2019. The Company’s top two customers accounted for 30% and 13% of the Company’s accounts receivable and an additional two customers each accounted for 11% of the Company’s accounts receivable as of September 30, 2020. Two customers accounted for approximately 29% and 25% of the Company’s accounts receivable as of December 31, 2019. The Company currently relies on a single supplier to produce a subcomponent used in its HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of processors, which in turn could materially affect the Company’s ability to generate revenue.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, bonus accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, inventory obsolescence and inventory valuation and valuation of accounts receivable and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of the COVID-19 pandemic on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers. Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2020. Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated statements of cash flows. September 30, 2020 2019 Cash and cash equivalents $ 18,884,468 $ 34,847,086 Restricted cash - non-current — 3,270,247 Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 18,884,468 $ 38,117,333 In October 2017, the Company received $3.0 million in gross proceeds from, and issued a subordinated convertible promissory note (the “QNAH Convertible Note”) in that principal amount to, QIAGEN North American Holdings, Inc. (“QNAH”). Amounts included in restricted cash represented those required to be set aside in escrow under the terms of the MidCap Term Loan to collateralize the payment that was due upon maturity of the QNAH Convertible Note (see Note 8). The balance of restricted cash was released to the Company on June 25, 2020 in conjunction with the extinguishment of the QNAH Convertible Note with proceeds from the SVB Term Loan (see Note 8). Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The NuvoGen obligation relates to an asset purchase transaction with a then-common stockholder of the Company. As of September 30, 2020, the estimated aggregate fair value of the NuvoGen obligation is approximately $4.5 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates. The estimated fair value of the NuvoGen obligation represents a Level 3 measurement. Leases Effective January 1, 2019, the Company accounts for its leases under Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) 842. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the condensed consolidated balance sheets as both right-of-use assets and lease liabilities, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and right-of-use assets are amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For financing leases, interest on the lease liability and the amortization of the right-of-use asset result in front-loaded expense over the lease term. Variable lease expenses are recorded to rent expense as incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components for all classes of assets currently under lease, including facilities, copiers and computer equipment. The Company excludes short-term leases having initial terms of 12 months or less from as an accounting policy election and recognizes rent on short-term leases on a straight-line basis over the lease term for these leases. Recently Adopted Accounting Pronouncements In August 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-13, Fair Value Measurement – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB issued ASU No. 2018-18, which amended ASC 808, Collaborative Arrangements Revenue from Contracts with Customers New Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of September 30, 2020: In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to transactions affected by reference rate reform if certain criteria are met. These transactions include: contract modifications, hedging relationships, and sale or transfer of debt securities classified as held-to-maturity. Entities may apply the provisions of the new standard as of the beginning of the reporting period when the election is made (i.e. as early as the first quarter 2020). Unlike other topics, the provisions of this update are only available until December 31, 2022, when the reference rate replacement activity is expected to have completed. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures and has yet to elect an adoption date. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Inventory

Inventory	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the dates indicated: September 30, December 31, 2020 2019 Raw materials $ 1,130,443 $ 872,947 Work in process 165,447 151,351 Finished goods 270,433 284,772 Total gross inventory 1,566,323 1,309,070 Less inventory allowance (27,770 ) (39,403 ) $ 1,538,553 $ 1,269,667 For the three and nine months ended September 30, 2020, the Company recorded adjustments to provision for excess inventory of $10,530 and $12,202, respectively. For the three and nine months ended September 30, 2019, the Company recorded adjustments to provision for excess inventory of $81,582 and $126,582, respectively. Adjustments in these periods to the allowance for estimated shrinkage, obsolescence and excess inventory have been included in cost of revenue in the accompanying condensed consolidated statements of operations. HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation as of September 30, 2020 was $104,950 compared to $79,338 as of December 31, 2019.

Fair Value Instruments

Fair Value Instruments	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Instruments	Note 4. Fair Value Instruments Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2020 and December 31, 2019 in the fair value hierarchy: September 30, 2020 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 18,803,851 $ — $ — $ 18,803,851 Investments available-for-sale at fair value U.S. Treasury securities 3,238,088 — — 3,238,088 Corporate debt securities — 8,394,072 — 8,394,072 Total $ 22,041,939 $ 8,394,072 $ — $ 30,436,011 December 31, 2019 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 7,217,096 $ — $ — $ 7,217,096 Investments available-for-sale at fair value U.S. Treasury securities 5,961,983 — — 5,961,983 Corporate debt securities — 19,448,239 — 19,448,239 Total $ 13,179,079 $ 19,448,239 $ — $ 32,627,318 There are no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three and nine months ended September 30, 2020 or for the year ended December 31, 2019. Level 1 instruments include investments in money market funds and U.S. Treasuries. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include corporate debt securities. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g., indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for the nine-month period ended September 30, 2020 or the year-ended December 31, 2019 and did not have any Level 3 financial assets or liabilities during either of these periods.

Available-for-Sale Securities

Available-for-Sale Securities	9 Months Ended
	Sep. 30, 2020
Investments Debt And Equity Securities [Abstract]
Available-for-Sale Securities	Note 5. Available-for-Sale Securities The Company’s portfolio of available-for-sale securities consists of U.S. Treasuries and high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities at September 30, 2020 and December 31, 2019: September 30, 2020 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 3,234,037 $ 4,051 $ — $ 3,238,088 Corporate debt securities 8,394,072 — — 8,394,072 Total available-for-sale securities $ 11,628,109 $ 4,051 $ — $ 11,632,160 December 31, 2019 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 5,962,224 $ 394 $ (635 ) $ 5,961,983 Corporate debt securities 19,448,239 — — 19,448,239 Total available-for-sale securities $ 25,410,463 $ 394 $ (635 ) $ 25,410,222 There were no gross unrealized losses relating to the Company’s available-for-sale securities investments as of September 30, 2020. The net adjustment to unrealized holding gains (losses) on available-for-sale securities, net of tax in other comprehensive income totaled $(17,501) and $4,060 for the three and nine months ended September 30, 2020, respectively and ($1,864) and $2,308 for the three and nine months ended September 30, 2019, respectively. Contractual maturities of debt investment securities at September 30, 2020 are shown below. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. Under 1 Year 1 to 2 Years Total U.S. Treasury securities $ 3,238,088 $ — $ 3,238,088 Corporate debt securities 8,394,072 — 8,394,072 Total available-for-sale securities $ 11,632,160 $ — $ 11,632,160 For debt securities, the Company determines whether it intends to sell or if it is more likely than not that it will be required to sell impaired securities. This determination considers current and forecasted liquidity requirements, regulatory and capital requirements and securities portfolio management. For all impaired debt securities for which there was no intent or expected requirement to sell, the evaluation considers all available evidence to assess whether it is likely the amortized cost value will be recovered. The Company conducts a regular assessment of its debt securities with unrealized losses to determine whether securities have other-than-temporary impairment considering, among other factors, the nature of the securities, credit rating or financial condition of the issuer, the extent and duration of the unrealized loss, expected cash flows of underlying collateral, market conditions and whether the Company intends to sell or it is more likely than not that the Company will be required to sell the debt securities. As the Company did not have any unrealized losses as of September 30, 2020, there were no

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net, consists of the following as of the dates indicated: September 30, December 31, 2020 2019 Furniture & fixtures $ 1,082,717 $ 1,089,371 Leasehold improvements 1,943,534 1,987,997 Equipment used in manufacturing 2,225,122 2,305,340 Equipment used in research & development 2,473,854 2,134,019 Equipment used in the field 208,005 182,762 Software 418,251 374,812 Property and equipment 8,351,483 8,074,301 Less: accumulated depreciation and amortization (6,824,785 ) (5,834,168 ) $ 1,526,698 $ 2,240,133 Depreciation and leasehold improvement amortization expense was approximately $0.3 million and $1.0 million for the three and nine months ended September 30, 2020, respectively, and approximately $0.3 million and $0.9 million for the three and nine months ended September 30, 2019, respectively.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2020
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consist of the following as of the dates indicated: September 30, December 31, 2020 2019 Accrued employee bonuses $ 331,642 $ 900,740 Payroll and employee benefit accruals 643,730 469,530 Accrued professional fees 102,551 43,850 Accrued interest 55,691 245,350 Accrued rebate 60,694 — Other accrued liabilities 192,517 210,826 $ 1,386,825 $ 1,870,296

Debt Obligations

Debt Obligations	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt Obligations	Note 8. Debt Obligations Current portion of long-term debt, net, consisted of the following as of the dates indicated: September 30, December 31, 2020 2019 Convertible note, net of debt issuance costs $ — $ 2,987,667 SVB Term Loan payable, net of discount and debt issuance costs 1,000,000 — PPP Loan 855,990 — Insurance Note Payable 410,894 — $ 2,266,884 $ 2,987,667 Long-term debt, net of current portion and discount and debt issuance costs, consisted of the following as of the dates indicated: September 30, December 31, 2020 2019 MidCap Term Loan payable, net of discount and debt issuance costs $ — $ 6,871,545 SVB Term Loan payable, net of discount and debt issuance costs 8,585,975 — PPP Loan 861,010 — $ 9,446,985 $ 6,871,545 MidCap Credit Facility On March 26, 2018 (the “MidCap Closing Date”), the Company entered into a Credit and Security Agreement (Term Loan) (the “MidCap Term Loan”) and a Credit and Security Agreement (Revolving Loan) (the “MidCap Revolving Loan” and together with the MidCap Term Loan, the “MidCap Credit Facility”) with MidCap Financial Trust, as agent. MidCap Financial Trust subsequently assigned its rights and obligations as agent to MidCap Funding IV Trust. On February 26, 2020 (the “Amendment Effective Date”), the Company entered into (i) an amendment to the MidCap Term Loan (the “MidCap Term Loan Amendment”), and (ii) an amendment to the MidCap Revolving Loan (the “MidCap Revolving Loan Amendment,” and together with the MidCap Term Loan Amendment, the “Amendments”). The MidCap Term Loan Amendment extended the interest only payments on the term loan advance by an additional 11 months, with principal on the term loan advance payable in 25 equal monthly installments beginning March 1, 2021 until paid in full on March 1, 2023. The MidCap Term Loan Amendment also provided that if the Company achieved a stated revenue milestone for the 12-month period ending on December 31, 2020, the interest-only period would be further extended by an additional four months, with principal on the term loan advance then payable in 21 equal monthly installments beginning July 1, 2021. QNAH Convertible Note Agreement In October 2017, the Company issued a subordinated convertible promissory note to QNAH in the principal amount of $3.0 million against receipt of cash proceeds equal to such principal amount. On June 25, 2020 in connection with the closing of the SVB Term Loan, the Company repaid in full the QNAH Convertible Note, in the aggregate amount of approximately $3.2 million. Extinguishment of MidCap Credit Facility and QNAH Convertible Note upon SVB Term Loan Closing On June 25, 2020, the Company repaid all principal and interest amounts outstanding under the MidCap Credit Facility in an aggregate amount equal to approximately $7.5 million, including collateral agent legal fees and prepayment fees. The repayment was funded with net proceeds from the SVB Term Loan (see description of the SVB Term Loan below). As a result of the repayment, the Company recorded a loss on extinguishment of the MidCap Credit Facility and the QNAH Convertible Note of approximately $0.5 million, including remaining unamortized discounts of $0.3 million and prepayment and other MidCap Credit Facility and QNAH Convertible Note lender fees and issuance costs in other expense in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2020. All obligations under the MidCap Credit Facility and the QNAH Convertible Note were terminated upon extinguishment of the MidCap Credit Facility. SVB Term Loan On June 24, 2020 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”), by and among the Company and Silicon Valley Bank (“SVB”), as lender, which provides a secured term loan in the principal amount of $10.0 million. The proceeds from the SVB Term Loan were fully funded on the June 25, 2020. The proceeds from the SVB Term Loan, together with cash on hand, were used to repay in full all outstanding amounts and fees due under the MidCap Credit Facility and the QNAH Convertible Note. The SVB Term Loan bears interest at a floating rate equal to the greater of 2.50% above the Prime Rate (as defined in the Loan Agreement) and 5.75%. Interest on the SVB Term Loan is due and payable monthly in arrears. The SVB Term Loan has interest-only payments through June 30, 2021. The interest only period may be extended for six months upon the achievement of an equity milestone as fully defined in the Loan Agreement. The ultimate interest-only period will be followed by equal monthly payments of principal and interest through the maturity date of December 1, 2023. Prepayments of the SVB Term Loan, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date, 2.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date but on or prior to the second anniversary of the Closing Date, and 1.0% of principal prepaid if prepayment occurs after the second anniversary of the Closing Date and prior to the maturity date. Upon termination of the Loan Agreement, the Company is required to pay a final fee equal to 8.00% of the principal amount of the SVB Term Loan. The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company’s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the Loan Agreement. The Loan Agreement contains customary affirmative covenants and customary negative covenants limiting the Company’s ability and the ability of the Company’s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. The Company must also comply with a financial covenant requiring the Company to maintain unrestricted cash at an account with SVB of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. The Loan Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company’s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, SVB may declare all or a portion of the Company’s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 5.0%. In connection with the Loan Agreement, the Company granted to SVB a warrant to purchase up to 643,413 shares of the Company’s common stock at a purchase price of $0.7771 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. The fair value of the warrant on the date of issuance was approximately $0.4 million, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the SVB Term Loan. The Company recognized approximately $1.2 million of debt discount associated with the SVB Term Loan, resulting from fees and debt issuance costs, inclusive of the fair value of warrants issued, in long-term debt, net in the as of September 30, 2020. Amortization of the debt discount associated with the SVB Term Loan was $0.1 million for both the three and nine months ended September 30, 2020 and was included in interest expense in the . The remaining principal repayments due under the SVB Term Loan as of September 30, 2020 are as follows for each fiscal year: 2020 $ - 2021 2,000,000 2022 4,000,000 2023 4,000,000 Total SVB Term Loan payments 10,000,000 Less discount and deferred financing costs (1,214,025 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 9,585,975 Paycheck Protection Program Loan On April 21, 2020, the Company received proceeds from a loan in the amount of $1,717,000 from SVB, as lender, pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act. The PPP Loan is evidenced by a promissory note (the “Note”), which contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties or terms of the PPP Loan documents. The PPP Loan matures on April 21, 2022 and bears interest at an annual rate of 1%. Beginning on March 21, 2021, the Company is required to make 14 equal monthly payments of principal and interest. The PPP Loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The proceeds from the PPP Loan may only be used for payroll costs (including benefits), rent and utility obligations, and interest on certain of the Company’s other debt obligations. All or a portion of the PPP Loan may be forgiven by the U.S. Small Business Administration (“SBA”) upon application and documentation by the Company of expenditures in accordance with the SBA requirements. Under the CARES Act and PPP Flexibility Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the 24-week period beginning on the date of loan approval. For purposes of the PPP, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if a Company’s full-time headcount declines, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25% during the measurement period, unless certain safe harbors are satisfied. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal and interest. The Company applied for full PPP Loan forgiveness in October 2020. However, there can be no assurance given that the Company will obtain forgiveness of the PPP Loan in whole or in part. In order to apply for the PPP Loan, the Company certified that, among other things, the current economic uncertainty made the PPP Loan request necessary to support its ongoing operations. In addition, PPP loans under the CARES Act may be subject to certain rules, regulations and Standard Operating Procedures (“SOPs”) applicable to the SBA’s Section 7(a) Loan Program, which includes PPP loans under the CARES Act. The interpretation and applicability of these rules, regulations and SOPs in unclear, as some of them have not been referenced in the CARES Act itself or in the guidance and interpretations issued by the SBA to date. If it is determined that the Company was not eligible to receive the PPP Loan, or that the Company has not adequately complied with the rules, regulations and SOPs applicable to the SBA’s Section 7(a) Loan Program, the Company could be subject to penalties and could be required to repay the PPP Loan in its entirety. If the Company were required to repay the PPP Loan in its entirety, the Company’s liquidity would be reduced. Insurance Note On April 27, 2020, the Company entered into a commercial financing agreement to extend the payment period related to its director and officer insurance policy. The Insurance Note required a down payment to be made upon signing the agreement equal to approximately $0.2 million. The unpaid premium balance of approximately $0.7 million was financed at an annual rate of 3.61%. The Insurance Note is being repaid in nine equal monthly payments of principal and interest beginning on June 6, 2020. The Insurance Note contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties or terms of the Insurance Note documents. The Insurance Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	Note 9. Revenue from Contracts with Customers Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and nine months ended September 30, 2020 and 2019 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Product revenue: Instruments $ 71,742 $ 414,491 $ 563,396 $ 1,100,606 Consumables 764,605 1,058,386 2,091,848 2,218,674 Total product revenue 836,347 1,472,877 2,655,244 3,319,280 Product-related services revenue: Custom RUO assay design 238,502 2,129,251 1,210,968 3,978,428 RUO sample processing 626,219 708,915 1,551,519 4,100,208 Total product-related services revenue 864,721 2,838,166 2,762,487 8,078,636 Total product and product-related services revenue $ 1,701,068 $ 4,311,043 $ 5,417,731 $ 11,397,916 Because the Company’s agreements for product and product-related services revenue have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations. Sale of Instruments and Consumables The delivery of each instrument and related installation and calibration are considered to be a single performance obligation, as the HTG EdgeSeq instrument must be professionally installed and calibrated prior to use. Instrument product revenue is generally recognized upon installation and calibration of the instrument by field service engineers, which represents the point at which the customer has the ability to use the instrument and has accepted the asset. Installation generally occurs within one month of instrument shipment. The delivery of each consumable is a separate performance obligation. Consumables revenue is recognized upon transfer of control, which represents the point when the customer has legal title and the significant risks of ownership of the asset. The Company’s standard terms and conditions provide that no right of return exists for instruments and consumables, unless replacement is necessary due to delivery of defective or damaged product. Customer payment terms vary but are typically between 30 and 90 days of revenue being earned from shipment or delivery, as applicable. Shipping and handling fees charged to the Company’s customers for instruments and consumables shipped are included in the accompanying condensed consolidated statements of operations as part of product and product-related services revenue. Shipping and handling costs for sold products shipped to the Company’s customers are included in the accompanying condensed consolidated statements of operations as part of cost of product and product-related services revenue. For sales of consumables in the United States, standard delivery terms are FOB shipping point, unless otherwise specified in the customer contract, reflecting transfer of control to the customer upon shipment. Standard delivery terms for sales to customers outside of the United States are FOB delivery point, unless otherwise specified in the customer contract. The Company has elected the practical expedient to account for shipping and handling as activities to fulfill the promise to transfer the consumables. The Company uses a most likely amount approach to estimate variable consideration arising from its rebate program. The Company’s variable consideration from its rebate program is constrained. The Company provides instruments to certain customers under reagent rental agreements. Under these agreements, the Company installs an instrument in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances, the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. The Company measures progress toward complete satisfaction of this performance obligation to provide the instrument and deliver the consumables using an output method based on the number of consumables delivered in relation to the total consumables to be provided under the reagent rental agreement. This is considered to be representative of the delivery of outputs under the arrangement and the best measure of progress because the customer benefits from the instrument only in conjunction with the consumables. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. The cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase, in which case the instrument would be expensed as cost of product and product-related services RUO Sample Processing The Company also provides sample preparation and processing services and molecular profiling of retrospective cohorts for its customers through its VERI/O laboratory, whereby the customer provides samples to be processed using HTG EdgeSeq technology specified in the order. Customers are charged a per sample fee for sample processing services which is recognized as revenue upon delivery of a data file to the customer showing the results of testing and completing delivery of the agreed upon service. This is when the customer can use and benefit from the results of testing and the Company has the present right to payment. Custom RUO Assay Design and Related Agreements The Company enters into custom RUO assay design agreements that may generate up-front fees and subsequent payments that might be earned upon completion of design process phases. The Company measures progress toward complete satisfaction of its performance obligation to perform custom RUO assay design using an output method based on the costs incurred to date compared with total expected costs, as this is representative of the delivery of outputs under the arrangements and the best measure of progress. However, because in most instances the assay design fees are contingent upon completion of each phase of the design project and the decision of the customer to proceed to the next phase, the amount to be included in the transaction price and recognized as revenue is limited to that which the customer is contractually obligated to pay upon completion of that phase, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company did not recognize any custom RUO assay design revenue from performance obligations that were satisfied in previous periods for either the three and nine months ended September 30, 2020, compared with $0 and $41,137 for the three and nine months ended September 30, 2019, respectively. Collaborative Development Services Revenue The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606, Revenue from Contracts with Customers and ASC 808, Collaborative Arrangements to determine the appropriate recognition of revenue under our collaborative research, development and commercialization agreements that contain multiple elements. For the three and nine months ended September 30, 2020 and 2019, collaborative development services revenue was generated through statements of work entered into under the Governing Agreement with QML as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Collaborative development services $ 76,030 $ 1,093,750 $ 548,135 $ 3,006,022 Master Assay Development, Commercialization and Manufacturing Agreement In November 2016, the Company entered into the Governing Agreement, which created the framework for QML and the Company to combine their technological and commercial strengths to offer biopharmaceutical companies a complete NGS-based solution for the development, manufacture and commercialization of companion diagnostic assays. Under the Governing Agreement, the parties jointly sought companion diagnostic programs with biopharmaceutical companies, with QML entering into sponsor project agreements with interested biopharmaceutical companies for specified projects, and QML and the Company entering into statements of work which set forth the rights and obligations of QML and the Company with respect to each project. In November 2019, the Company elected to terminate the Governing Agreement with QML as a result of QML’s material breach of the Governing Agreement, including QML’s failure to develop an in vitro diagnostic (“IVD”) version of its GeneReader sequencing platform for development of PDP Assays. The Company’s termination of the Governing Agreement did not terminate active statements of work under the Governing Agreement. The Company has determined that SOW Two and SOW Three (each defined below) are collaborative arrangements and that QML meets the definition of a customer under ASC 606. Additionally, each SOW is a separate contract with a single performance obligation to provide development services. Under each SOW, QML pays the Company a monthly fee for development work performed by the Company and its subcontractors (collectively, the “Monthly Fee”). The Monthly Fee is based on the employee and materials costs incurred during the month, which is subject to significant variability from period to period and unknown until the costs are incurred. Therefore, the Monthly Fee, which is based on use of hours and costs as a measure of progress, is included in the transaction price and recognized as revenue over time when the costs are incurred, and the Monthly Fee is billed to QML. It is at this time that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company and QML also share any net profits resulting from performance of the development work as determined pursuant to the Governing Agreement. Such profit-sharing payment(s) are deemed to be variable consideration using the expected value method and are included in the transaction price upon completion of the respective SOW deliverables, acceptance of corresponding deliverables, and the mutual agreement by QML and the Company on the calculation of net profit, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Because each SOW has an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations for each SOW. Statement of Work No. Two In October 2017, the Company and QML entered into the second statement of work under the Governing Agreement (“SOW Two”), which was made effective as of June 2, 2017 (“Onset Date”). The Company and QML amended SOW Two twice in August 2018 and two additional times, in September 2018 and in February 2019. SOW Two addresses development activities conducted by the Company and QML since the Onset Date and those expected to be further conducted by the parties in connection with what is expected to be a multi-stage project leading to the potential development and commercialization of an NGS-based companion diagnostic assay in support of one or more therapeutic development and commercialization programs for a third-party biopharmaceutical company. The initial-phase investigational-use-only (“IUO”) development activities under SOW Two and the first three amendments related to next phases, which include the use of the IUO assay developed in the initial-phase in a retrospective clinical trial and in additional disease indications, have been completed. The fourth amendment of SOW Two, effective as of February 5, 2019, contemplates the use of the IUO assay in multiple biopharmaceutical company clinical trials and additional development activities which could potentially be included in a future companion diagnostic regulatory submission. As of September 30, 2020, development activities agreed upon in the fourth amendment are ongoing and expected to be completed in the fourth quarter of 2020. Revenue of approximately $0.1 million and $0.5 million inclusive of SOW Two Monthly Fees and approximately $0.1 million and $0.1 million of SOW Two profit-sharing payments has been included in collaborative development services revenue in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2020, respectively. Revenue of approximately $0.6 million and $2.2 million, inclusive of SOW Two Monthly Fees and approximately $0.3 million and $0.4 million of SOW Two profit-sharing payments has been included in collaborative development services revenue in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2019, respectively. Accounts receivable relating to SOW Two of approximately $0.1 million and $0.2 million remained in the accompanying condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, respectively. Costs relating to development activities conducted by the Company pursuant to SOW Two of less than $0.1 million and approximately $0.4 million have been included in research and development expense in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2020, respectively, compared with approximately $0.2 million and $1.3 million for the three and nine months ended September 30, 2019, respectively. Statement of Work No. Three In January 2018, the Company and QML entered into a third statement of work under the Governing Agreement (“SOW Three”) and amended SOW Three in September 2018. SOW Three relates to development activities for an NGS-based clinical-trial assay (“SOW Three Project”) in connection with a sponsor project agreement between QML and a pharmaceutical company (“Pharma Three”). Initial assay development activities under SOW Three have been completed, and the first amendment to SOW Three provides for the development of an IUO assay, subsequent retrospective testing of clinical trial samples, design verification and, subject to satisfactory achievement of relevant performance and regulatory milestones, regulatory submissions in the United States and European Union necessary for the commercialization of a companion diagnostic for a corresponding Pharma Three drug. As of September 30, 2020, the Company and QML are on hold pending customer decision as to whether to proceed with next phase contract activities. There was no revenue recognized, or development costs incurred relating to SOW Three for the three and nine months ended September 30, 2020. Revenue of approximately $0.5 million and $0.8 million reflecting SOW Three Monthly Fees has been included in collaborative development services revenue in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2019, respectively. Accounts receivable relating to SOW Three of $0 and approximately $0.8 million remained in the condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, respectively. Costs relating to development activities conducted by the Company pursuant to SOW Three of approximately $0.3 million and $0.6 million have been included in research and development expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2019, respectively. Contract Assets Contract assets represent the Company's right to consideration in exchange for goods or services that the Company has transferred to a customer, for which rights to payment are conditional upon something other than the passage of time. Contract assets of approximately $42,000 and $0 were included in prepaid expenses and other in the accompanying condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, respectively. Contract Liabilities The Company receives up-front payments from customers for custom RUO assay design services, and occasionally for sample processing services. Payments for instrument extended warranty contracts are made in advance as are payments for certain agreed-upon capital purchases required for collaborative development service projects. The Company recognizes such up-front payments as a contract liability. The contract liability is subsequently reduced at the point in time that the data file is delivered for sample processing services or as the Company satisfies its performance obligations over time for RUO assay design, collaborative development and extended warranty services. Contract liabilities of approximately $0.5 million and $0.6 million were included in contract liabilities – current and other non-current liabilities in the accompanying condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, respectively. The Company expects approximately $0.3 million of deferred revenue to be realized within the next 12 months and the remaining $0.2 million to be realized prior to December 31, 2022. Changes in the Company’s contract liability were as follows as of the dates indicated: Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2020 $ 95,148 $ 66,216 $ 438,090 $ 599,454 Deferral of revenue 335,265 459,385 77,104 871,754 Recognition of deferred revenue (325,181 ) (525,601 ) (95,670 ) (946,452 ) Balance at September 30, 2020 $ 105,232 $ — $ 419,524 $ 524,756 Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2019 $ 116,547 $ 50,000 $ 244,400 $ 410,947 Deferral of revenue 126,425 671,885 463,814 1,262,124 Recognition of deferred revenue (172,610 ) (707,641 ) (229,192 ) (1,109,443 ) Balance at September 30, 2019 $ 70,362 $ 14,244 $ 479,022 $ 563,628

Other Agreements

Other Agreements	9 Months Ended
	Sep. 30, 2020
Other Agreements [Abstract]
Other Agreements	Note 10. Other Agreements NuvoGen Obligation Pursuant to the Company’s asset purchase agreement with NuvoGen Research, LLC (“NuvoGen”), as amended, the Company is obligated to pay NuvoGen the greater of $400,000 or 6% of annual revenue until the obligation is paid in full. In addition to fixed quarterly payments of $100,000, revenue-based payments of less than $0.1 million and approximately $0.2 million were payable as of September 30, 2020 and December 31, 2019, respectively. There have been no significant modifications to the terms and conditions of the Company’s NuvoGen obligation since the disclosures made in Part II, Item 8, Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2020. Remaining minimum payments to be made in 2020 include $6,626 of revenue-based payments payable as of September 30, 2020 and the fourth quarter 2020 minimum payment. Minimum payments to be made in 2021 include an estimate of additional revenue-based payments to be made in the first, second and third quarters of 2021 relating to revenue generated in the fourth quarter of 2020 and in the first and second quarters of 2021, estimated using revenue generated in the same quarters in 2019 and 2020. Minimum payments for the remaining periods include only the minimum quarterly payments to be made in each period. Actual payments could vary from what is shown in the table, to the extent that 6% of the Company’s annual revenue in 2021 and beyond exceeds $400,000. The remaining minimum payments to be made to NuvoGen as of September 30, 2020 are as follows for each fiscal year: 2020 $ 106,626 2021 639,323 2022 400,000 2023 400,000 2024 400,000 2025 and beyond 3,073,428 Total NuvoGen obligation payments 5,019,377 Plus interest accretion 82,540 Total NuvoGen obligation, net $ 5,101,917 The Company has recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, the Company’s estimate of its effective borrowing rate for similar obligations. The unamortized debt discount was $(82,540) and $(92,311) at September 30, 2020 and December 31, 2019, respectively. Discount accreted during the three and nine months ended September 30, 2020 was $(3,115) and $(9,771), respectively, compared with $(3,790) and $(10,273) for the three and nine months ended September 30, 2019, respectively. Other Agreements There have been no significant modifications or financial events relating to the development agreement entered into by the Company with Illumina, Inc. since the disclosures made in Part II, Item 8, Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2020.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss per Share	Note 11. Net Loss Per Share Basic loss per common share is computed by dividing net loss allocable to common stockholders by the weighted average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per In connection with the Securities Purchase Agreement (see Note 13), the Company issued and sold an aggregate of 5,411,687 pre-funded warrants exercisable for an aggregate of 5,411,687 shares of common stock. The total exercise price of the pre-funded warrants is $0.65 per share, $0.64 of which was pre-funded and paid to the Company upon issuance of the pre-funded warrants. The remaining exercise price of the pre-funded warrants is $0.01 per share. The remaining pre-funded warrants are immediately exercisable and do not expire. As the remaining shares underlying the pre-funded warrants are issuable for nominal consideration of $0.01 per share, The following outstanding options, warrants, restricted stock units and debt conversion option were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2020 2019 Options to purchase common stock 7,485,489 2,940,990 Common stock warrants 880,328 236,915 Restricted stock units 204,051 247,079 QNAH convertible note - 794,665

Warrants

Warrants	9 Months Ended
	Sep. 30, 2020
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 12. Warrants In connection with certain of its redeemable convertible preferred stock issuances, convertible debt financings and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock, which have since been converted to common stock warrants. In September 2019, in connection with the Securities Purchase Agreement (see Note 13), the Company issued and sold an aggregate of 5,411,687 pre-funded warrants exercisable for an aggregate of 5,411,687 shares of common stock. The total exercise price of the pre-funded warrants is $0.65 per share, $0.64 of which was pre-funded and paid to the Company upon issuance of the pre-funded warrants. The remaining exercise price of the pre-funded warrants is $0.01 per share. In March 2020, 3,176,762 of the pre-funded warrants were exercised for proceeds of $31,768. As of September 30, 2020, the remaining pre-funded warrants remain outstanding and are exercisable by the holders at any time. In connection with the SVB Term Loan Agreement (see Note 8), the Company granted to SVB a warrant to purchase up to 643,413 shares of the Company’s common stock at a purchase price of $0.7771 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. The following table shows the common stock warrants outstanding as of September 30, 2020: Warrant Issuance Date Shares of Common Exercise Price/Share Expiration Date August 2014 28,713 $ 23.51 2024 December 2014 144,772 14.00 2022 March 2016 45,307 2.76 2026 March 2018 18,123 7.73 2028 September 2019 2,234,925 0.01 N/A June 2020 643,413 0.7771 2030

Stockholders Deficit

Stockholders Deficit	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Deficit	Note 13. Stockholders’ Deficit Equity Offerings Securities Purchase Agreement In September 2019, concurrently with the closing of an underwritten public offering, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers, in a private placement transaction, an aggregate of 5,411,687 pre-funded warrants to purchase up to an aggregate of 5,411,687 shares of our common stock (“Warrant Shares”), at a price of $0.64 per warrant (which $0.64 price relates to the pre-funded portion of the total $0.65 exercise price per share). Each pre-funded warrant has a remaining exercise price of $0.01 per share and became immediately exercisable upon issuance, subject to certain beneficial ownership limitations. The exercise price of the pre-funded warrants will be subject to adjustment in the event of any stock dividends and splits, recapitalization, reorganization or similar transaction, as described in the pre-funded warrants. The pre-funded warrants are exercisable on a “cashless” basis in certain circumstances. The pre-funded warrants and the Warrant Shares were not registered under the Securities Act and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. Pursuant to the Securities Purchase Agreement, the Company filed a registration statement on Form S-3 on October 11, 2019 to register the resale of the Warrant Shares, which registration statement was declared effective by the SEC on November 26, 2019. Each Purchaser was an “accredited investor” as defined in Rule 501(a) under the Securities Act. Cantor Fitzgerald & Co. (the “Placement Agent”) acted as the sole placement agent in connection with the private placement of the warrants. Pursuant to a Placement Agency Agreement between the Company and the Placement Agent, the Company agreed to pay the Placement Agent a cash fee equal to 6% of the gross proceeds from the sale of the pre-funded warrants, and to provide reimbursement for certain out-of-pocket expenses. Upon closing, the Company received approximately $3.1 million in net proceeds from the sale of the pre-funded warrants in the private placement, which did not include proceeds subsequently received or that may be received upon exercise of the pre-funded warrants, after deducting the Placement Agent fee and other expenses. In March 2020, 3,176,762 of the pre-funded warrants were exercised for additional proceeds of $31,768. ATM Offering In November 2019, the Company entered into a Controlled Equity Offering Sales Agreement (the “Cantor Sales Agreement”) with Cantor as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its common stock, par value $0.001 per share, by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act (the “ATM Offering”). The shares are offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-229045). During the nine months ended September 30, 2020, the Company sold 10,436,016 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $6.7 million. After deferred offering costs included as non-current assets in the condensed balance sheets as of December 31, 2019 of approximately $0.1 million and paying sales commissions owed in connection with the ATM Offering of approximately $0.2 million, the Company’s aggregate net proceeds for the nine months ended September 30, 2020 were approximately $6.4 million. Exchange and Private Placement On February 25, 2020, the Company entered into an Exchange and Purchase Agreement (the “Exchange Agreement”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to (i) issue to the Investors an aggregate of 41,100 shares of its newly designated Series A Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred”), in exchange for the Investors surrendering to the Company for cancellation an aggregate of 4,110,000 shares of its common stock (the “Exchange”) and (ii) sell and issue to the Investors an aggregate of 10,170 shares of Series A Preferred for an aggregate purchase price of $600,030, or $59.00 per share (the “Private Placement”). The common stock acquired in the Exchange was immediately retired. Each share of Series A Preferred is convertible into 100 shares of the Company’s common stock, subject to proportional adjustment and beneficial ownership limitations. In June 2020, certain of the Investors elected to convert 27,500 shares of Series A Preferred to common stock in the aggregate, resulting in the issuance of 2,750,000 shares of the Company’s common stock. The remaining 23,770 Series A Preferred shares remain outstanding as of September 30, 2020. In the event of the Company’s liquidation, dissolution or winding up, holders of Series A Preferred will participate pari passu with any distribution of proceeds to holders of the Company’s common stock. Holders of Series A Preferred are entitled to receive dividends on shares of Series A Preferred equal (on an as converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock. Shares of Series A Preferred generally have no voting rights, except as required by law. LP Purchase Agreement On March 24, 2020, the Company entered into a purchase agreement ("LP Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to which, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right to sell to Lincoln Park up to $20.0 million of shares of its common stock (“Purchase Shares”) from time to time over the 36-month term of the LP Purchase Agreement. The purchase price of the Purchase Shares will be based on recent closing prices of the Company’s common stock at the time of sale. The Company issued Lincoln Park an aggregate of 615,384 shares of its common stock as consideration for their purchase commitment pursuant to the LP Purchase Agreement. The Company did not receive cash proceeds from the issuance of such shares. The value of this commitment consideration, as well as related transaction costs of approximately $0.1 million have been included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations for the nine months ended September Stock-based Compensation Equity Incentive Plans In May 2015, 940,112 shares were reserved for issuance under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”). There were no shares of the Company’s stock available for issuance under the 2014 Plan as of December 31, 2019, other than those reserved for inducement awards, as outlined below. On January 1, 2020, an additional 2,323,609 shares were registered for issuance under the 2014 Plan pursuant to an evergreen provision contained in the 2014 Plan. In May 2019, 200,000 shares were reserved for issuance under the 2014 Plan pursuant to an amendment approved by the Company’s Board of Directors pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules, to be used exclusively for the grant of awards to individuals who were not previously employees or non-employee directors of the Company, as inducement material to the individuals’ entering into employment with the Company (“Inducement Awards”). No new Inducement Awards may be granted under the 2014 Plan. In August 2020, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors, approved the 2020 Equity Incentive Plan (the “2020 Plan”) as a successor to and continuation of the 2014 Plan. Upon approval of the 2020 Plan, 11,170,288 shares, including 1,028,292 remaining shares reserved for issuance under the 2014 Plan (excluding shares available for the granting of inducement awards under the 2014 Plan’s inducement share pool), were reserved for issuance under the 2020 Plan. No new awards may be granted under the 2014 Plan. The 2020 Plan does not contain an evergreen provision. The Company’s Board of Directors determines the grant date for all awards granted under the 2020 Plan. The option exercise price of stock options granted is generally equal to the closing price of the Company’s common stock on the date of grant or on the employee’s hire date for new hire grants. All stock options granted have a ten-year term. The vesting period of stock options and RSUs is established by the Board of Directors but typically ranges between one and four years. A summary of the Company’s stock option activity for the nine months ended September 30, 2020 is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2019 2,904,898 $ 2.37 8.0 $ 781 Granted 5,766,000 0.52 Exercised - - $ - Forfeited (1,102,897 ) 1.01 Expired/Cancelled (82,512 ) 3.29 Balance at September 30, 2020 7,485,489 $ 1.13 8.9 $ 404 Exercisable at September 30, 2020 2,489,579 $ 1.98 7.4 $ 101 As of September 30, 2020, total unrecognized compensation cost related stock option awards was approximately $2.7 million, which is expected to be recognized over approximately 2.44 years. The following table summarizes restricted stock unit (“RSU”) award activity for the nine months ended September 30, 2020: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2019 223,745 $ 2.91 Granted 105,000 0.52 Released (97,819 ) 2.43 Forfeited (26,875 ) 2.75 Balance at September 30, 2020 204,051 $ 1.94 Vested and unissued at September 30, 2020 20,783 $ 2.21 Vested and unissued awards at September 30, 2020 represents RSU awards for which the vesting date was September 30, 2020, but for which issuance of the awards occurred in October 2020. As of September 30, 2020, the total unrecognized compensation cost related to RSU awards was approximately $0.3 million, which is expected to be recognized over approximately 1.93 years. Stock-based compensation expense recorded in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Selling, general and administrative $ 380,676 $ 226,645 $ 1,070,651 $ 625,821 Research and development 884 74,652 81,374 181,336 Cost of product and product-related services revenue 5,389 15,258 11,717 37,976 $ 386,949 $ 316,555 $ 1,163,742 $ 845,133

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	Note 14. Leases Operating Leases T he Company leases office space and equipment under agreements classified as operating leases that expire on various dates through 2023. The Company’s most significant active leases as of September 30, 2020 are for office and manufacturing space in Tucson, Arizona, which expire in 2021. The Company also leases a development laboratory space in San Carlos, California, which expires in 2023. The Company’s leases do not include any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company’s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options. Annual rent increases are included in the calculation of the operating lease right-of-use assets. Variable expenses generally represent the Company’s share of the landlord’s operating expenses and are recorded when incurred. Incremental borrowing rates used to discount future lease payments in calculating lease liabilities were estimated by reference to the rate on the Company’s existing debt, as this represents the cost of borrowing for secured loans of similar duration. The Company does not have any operating lease arrangements where it acts as a lessor. The components of lease cost for operating leases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Operating leases Operating lease cost $ 182,287 $ 174,581 $ 570,163 $ 435,312 Variable lease cost 36,554 36,210 89,716 89,468 Operating lease expense 218,841 210,791 659,879 524,780 Short-term lease rent expense — — — 1,497 Total rent expense $ 218,841 $ 210,791 $ 659,879 $ 526,277 The table below summarizes other information related to the Company’s operating leases: Nine Months Ended September 30, 2020 2019 Operating cash flows for operating leases $ 665,095 $ 550,024 Establishment of operating lease liabilities arising from obtaining right-of-use assets $ 21,078 $ 2,038,193 Weighted-average remaining lease term – operating leases 1.9 2.4 Weighted-average discount rate – operating leases 9.6 % 9.6 % As of September 30, 2020, remaining maturities of our operating leases, excluding short-term leases, are as follows: 2020 $ 218,157 2021 340,970 2022 281,232 2023 70,848 Total 911,207 Less present value discount (84,311 ) Operating lease liabilities, net $ 826,896 Financing Leases The Company has a number of computer and copier equipment leases that are classified as financing leases. Incremental borrowing rates used to discount future lease payments in calculating lease liabilities were estimated by reference to information received by the Company from bankers regarding estimated current borrowing rates for collateralized loans with similar amount and duration as the leases. The components of lease cost for financing leases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Financing leases Amortization of right-of-use assets $ 10,035 $ 10,128 $ 34,033 $ 36,908 Interest on lease liability 2,092 1,559 7,074 5,528 Total financing lease cost $ 12,127 $ 11,687 $ 41,107 $ 42,436 The table below summarizes other information related to the Company’s financing leases: Nine Months Ended September 30, 2020 2019 Weighted-average remaining lease term – financing leases 3.5 2.0 Weighted-average discount rate – financing leases 9.77 % 9.77 % As of September 30, 2020, remaining maturities of our financing leases are as follows: 2020 $ 10,445 2021 28,355 2022 20,716 2023 18,396 2024 16,080 Total 93,992 Less present value discount (14,737 ) Financing lease liabilities, net $ 79,255 At September 30, 2020, the Company had financing lease liabilities net of discount of $79,255, of which $26,620 was included in other current liabilities and $52,635 was included in other non-current liabilities, and financing right-of-use assets of $75,563, which were included in property and equipment, net, in the accompanying condensed consolidated balance sheet.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Product Warranty The following is a summary of the Company’s general product warranty liability, which is included in accrued liabilities in the accompanying condensed consolidated balance sheets as of the dates indicated. Expense relating to the recording of this reserve is recorded in cost of product and product-related services revenue within the accompanying condensed consolidated statements of operations. Nine Months Ended September 30, 2020 2019 Beginning balance $ 94,482 $ 63,461 Cost of warranty claims (19,310 ) (38,691 ) Increase in warranty reserve 12,423 64,637 Ending balance $ 87,595 $ 89,407

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
COVID-19 Pandemic	COVID-19 Pandemic On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (“COVID-19”) originating in Wuhan, China and the risks to the international community as the virus spreads globally. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. The full impact of the COVID-19 pandemic continues to evolve as of the date of this report and likewise the full impact of the pandemic on the Company’s financial condition, liquidity and future results of operations is uncertain. Management is actively monitoring the potential impact of the global situation on its financial condition, liquidity, operations, suppliers, industry and workforce. Given the daily evolution of the COVID-19 pandemic and the global responses to curb its spread, the Company is not able to fully estimate the effects of the COVID-19 pandemic on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and believes this period of reduced revenue will continue through at least the remainder of 2020 due to disruptions to its customers’ businesses as a result of the pandemic. The extent of this impact varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic. The Company has experienced very limited delays in its development efforts as a result of stay-at-home orders despite its efforts to prioritize the safety of its employees during this pandemic. The Company believes the COVID-19 pandemic will continue to impact its productivity, supply chains, distribution networks and other areas of its operation as ongoing concerns regarding the pandemic continue to disrupt the Company’s business and the businesses of its vendors, partners and customers . Although the Company cannot estimate the length and gravity of the impact of the COVID-19 pandemic at this time, the COVID-19 pandemic is expected to have a continuing adverse effect on the Company’s results of operations, financial position and liquidity for at least the remainder of 2020. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the COVID-19 pandemic. On April 21, 2020, the Company received proceeds from a loan in the amount of $1,717,000 from SVB, as lender, pursuant to the Paycheck Protection Program of the CARES Act (the “PPP loan”) (see Note 8). While there remains uncertainty as to the ultimate impact of the COVID-19 pandemic, the Company has considered the known impacts on its business as of the date of this report and has reflected any known or expected impacts in its accompanying condensed consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position.
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“U.S. GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The accompanying condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and disclosures required by U.S. GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2020.
Going Concern and Liquidity	Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year of the filing of this Quarterly Report on Form 10-Q with the SEC. The accompanying interim unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of the assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $186.9 million as of September 30, 2020. As of September 30, 2020, the Company had working capital of $28.4 million and long-term liabilities of $14.5 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured Loan and Security Agreement with Silicon Valley Bank (the “SVB Term Loan”), the PPP Loan, and a commercial financing agreement extending the payment period related to its director and officer insurance policy The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant requiring the Company to maintain a certain amount of unrestricted cash under its SVB Term Loan.
Principles of Consolidation	Principles of Consolidation The Company formed a French subsidiary, HTG Molecular Diagnostics France SARL (“HTG France”), in November 2018. The accompanying condensed consolidated financial statements include the accounts of the Company and this wholly-owned subsidiary after elimination of all intercompany transactions and balances as of September 30, 2020 and December 31, 2019.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents, available-for-sale debt securities and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The available-for-sale debt securities are comprised primarily of investments in U.S. Treasury and high-quality debt securities. The Company sells its instrument, related consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top two customers accounted for 24% and 10% of the Company’s total revenue for the three months ended September 30, 2020, compared with the Company’s top two customers accounting for 39% and 20% of the Company’s total revenue for the three months ended September 30, 2019. The Company’s top two customers accounted for 16% and 10% of the Company’s total revenue for the nine months ended September 30, 2020 compared with the Company’s top three customers accounting for 23%, 22% and 21% for the nine months ended September 30, 2019. The Company’s top two customers accounted for 30% and 13% of the Company’s accounts receivable and an additional two customers each accounted for 11% of the Company’s accounts receivable as of September 30, 2020. Two customers accounted for approximately 29% and 25% of the Company’s accounts receivable as of December 31, 2019. The Company currently relies on a single supplier to produce a subcomponent used in its HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of processors, which in turn could materially affect the Company’s ability to generate revenue.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, bonus accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, inventory obsolescence and inventory valuation and valuation of accounts receivable and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of the COVID-19 pandemic on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2020.
Restricted Cash	Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated statements of cash flows. September 30, 2020 2019 Cash and cash equivalents $ 18,884,468 $ 34,847,086 Restricted cash - non-current — 3,270,247 Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 18,884,468 $ 38,117,333 In October 2017, the Company received $3.0 million in gross proceeds from, and issued a subordinated convertible promissory note (the “QNAH Convertible Note”) in that principal amount to, QIAGEN North American Holdings, Inc. (“QNAH”). Amounts included in restricted cash represented those required to be set aside in escrow under the terms of the MidCap Term Loan to collateralize the payment that was due upon maturity of the QNAH Convertible Note (see Note 8). The balance of restricted cash was released to the Company on June 25, 2020 in conjunction with the extinguishment of the QNAH Convertible Note with proceeds from the SVB Term Loan (see Note 8).
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The NuvoGen obligation relates to an asset purchase transaction with a then-common stockholder of the Company. As of September 30, 2020, the estimated aggregate fair value of the NuvoGen obligation is approximately $4.5 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates. The estimated fair value of the NuvoGen obligation represents a Level 3 measurement.
Leases	Leases Effective January 1, 2019, the Company accounts for its leases under Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) 842. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the condensed consolidated balance sheets as both right-of-use assets and lease liabilities, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and right-of-use assets are amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For financing leases, interest on the lease liability and the amortization of the right-of-use asset result in front-loaded expense over the lease term. Variable lease expenses are recorded to rent expense as incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components for all classes of assets currently under lease, including facilities, copiers and computer equipment. The Company excludes short-term leases having initial terms of 12 months or less from as an accounting policy election and recognizes rent on short-term leases on a straight-line basis over the lease term for these leases.
Recently Adopted and New Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-13, Fair Value Measurement – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB issued ASU No. 2018-18, which amended ASC 808, Collaborative Arrangements Revenue from Contracts with Customers New Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of September 30, 2020: In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to transactions affected by reference rate reform if certain criteria are met. These transactions include: contract modifications, hedging relationships, and sale or transfer of debt securities classified as held-to-maturity. Entities may apply the provisions of the new standard as of the beginning of the reporting period when the election is made (i.e. as early as the first quarter 2020). Unlike other topics, the provisions of this update are only available until December 31, 2022, when the reference rate replacement activity is expected to have completed. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures and has yet to elect an adoption date. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated statements of cash flows. September 30, 2020 2019 Cash and cash equivalents $ 18,884,468 $ 34,847,086 Restricted cash - non-current — 3,270,247 Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 18,884,468 $ 38,117,333

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the dates indicated: September 30, December 31, 2020 2019 Raw materials $ 1,130,443 $ 872,947 Work in process 165,447 151,351 Finished goods 270,433 284,772 Total gross inventory 1,566,323 1,309,070 Less inventory allowance (27,770 ) (39,403 ) $ 1,538,553 $ 1,269,667

Fair Value Instruments (Tables)

Fair Value Instruments (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2020 and December 31, 2019 in the fair value hierarchy: September 30, 2020 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 18,803,851 $ — $ — $ 18,803,851 Investments available-for-sale at fair value U.S. Treasury securities 3,238,088 — — 3,238,088 Corporate debt securities — 8,394,072 — 8,394,072 Total $ 22,041,939 $ 8,394,072 $ — $ 30,436,011 December 31, 2019 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 7,217,096 $ — $ — $ 7,217,096 Investments available-for-sale at fair value U.S. Treasury securities 5,961,983 — — 5,961,983 Corporate debt securities — 19,448,239 — 19,448,239 Total $ 13,179,079 $ 19,448,239 $ — $ 32,627,318

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	9 Months Ended
	Sep. 30, 2020
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The Company’s portfolio of available-for-sale securities consists of U.S. Treasuries and high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities at September 30, 2020 and December 31, 2019: September 30, 2020 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 3,234,037 $ 4,051 $ — $ 3,238,088 Corporate debt securities 8,394,072 — — 8,394,072 Total available-for-sale securities $ 11,628,109 $ 4,051 $ — $ 11,632,160 December 31, 2019 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 5,962,224 $ 394 $ (635 ) $ 5,961,983 Corporate debt securities 19,448,239 — — 19,448,239 Total available-for-sale securities $ 25,410,463 $ 394 $ (635 ) $ 25,410,222
Summary of Contractual Maturities of Debt Investment Securities	Contractual maturities of debt investment securities at September 30, 2020 are shown below. Under 1 Year 1 to 2 Years Total U.S. Treasury securities $ 3,238,088 $ — $ 3,238,088 Corporate debt securities 8,394,072 — 8,394,072 Total available-for-sale securities $ 11,632,160 $ — $ 11,632,160

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net, consists of the following as of the dates indicated: September 30, December 31, 2020 2019 Furniture & fixtures $ 1,082,717 $ 1,089,371 Leasehold improvements 1,943,534 1,987,997 Equipment used in manufacturing 2,225,122 2,305,340 Equipment used in research & development 2,473,854 2,134,019 Equipment used in the field 208,005 182,762 Software 418,251 374,812 Property and equipment 8,351,483 8,074,301 Less: accumulated depreciation and amortization (6,824,785 ) (5,834,168 ) $ 1,526,698 $ 2,240,133

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consist of the following as of the dates indicated: September 30, December 31, 2020 2019 Accrued employee bonuses $ 331,642 $ 900,740 Payroll and employee benefit accruals 643,730 469,530 Accrued professional fees 102,551 43,850 Accrued interest 55,691 245,350 Accrued rebate 60,694 — Other accrued liabilities 192,517 210,826 $ 1,386,825 $ 1,870,296

Debt Obligations (Tables)

Debt Obligations (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Current Portion of Long-term Debt, Net	Current portion of long-term debt, net, consisted of the following as of the dates indicated: September 30, December 31, 2020 2019 Convertible note, net of debt issuance costs $ — $ 2,987,667 SVB Term Loan payable, net of discount and debt issuance costs 1,000,000 — PPP Loan 855,990 — Insurance Note Payable 410,894 — $ 2,266,884 $ 2,987,667
Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs	Long-term debt, net of current portion and discount and debt issuance costs, consisted of the following as of the dates indicated: September 30, December 31, 2020 2019 MidCap Term Loan payable, net of discount and debt issuance costs $ — $ 6,871,545 SVB Term Loan payable, net of discount and debt issuance costs 8,585,975 — PPP Loan 861,010 — $ 9,446,985 $ 6,871,545
Schedule of Remaining Principal Repayments due Under SVB Term Loan	The remaining principal repayments due under the SVB Term Loan as of September 30, 2020 are as follows for each fiscal year: 2020 $ - 2021 2,000,000 2022 4,000,000 2023 4,000,000 Total SVB Term Loan payments 10,000,000 Less discount and deferred financing costs (1,214,025 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 9,585,975

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Product and Product-Related Service Revenue from Sale of Instruments and Consumables	Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and nine months ended September 30, 2020 and 2019 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Product revenue: Instruments $ 71,742 $ 414,491 $ 563,396 $ 1,100,606 Consumables 764,605 1,058,386 2,091,848 2,218,674 Total product revenue 836,347 1,472,877 2,655,244 3,319,280 Product-related services revenue: Custom RUO assay design 238,502 2,129,251 1,210,968 3,978,428 RUO sample processing 626,219 708,915 1,551,519 4,100,208 Total product-related services revenue 864,721 2,838,166 2,762,487 8,078,636 Total product and product-related services revenue $ 1,701,068 $ 4,311,043 $ 5,417,731 $ 11,397,916
Schedule of Collaborative Development Services	Collaborative Development Services Revenue The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606, Revenue from Contracts with Customers and ASC 808, Collaborative Arrangements to determine the appropriate recognition of revenue under our collaborative research, development and commercialization agreements that contain multiple elements. For the three and nine months ended September 30, 2020 and 2019, collaborative development services revenue was generated through statements of work entered into under the Governing Agreement with QML as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Collaborative development services $ 76,030 $ 1,093,750 $ 548,135 $ 3,006,022
Schedule of Changes in Contract Liability	Changes in the Company’s contract liability were as follows as of the dates indicated: Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2020 $ 95,148 $ 66,216 $ 438,090 $ 599,454 Deferral of revenue 335,265 459,385 77,104 871,754 Recognition of deferred revenue (325,181 ) (525,601 ) (95,670 ) (946,452 ) Balance at September 30, 2020 $ 105,232 $ — $ 419,524 $ 524,756 Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2019 $ 116,547 $ 50,000 $ 244,400 $ 410,947 Deferral of revenue 126,425 671,885 463,814 1,262,124 Recognition of deferred revenue (172,610 ) (707,641 ) (229,192 ) (1,109,443 ) Balance at September 30, 2019 $ 70,362 $ 14,244 $ 479,022 $ 563,628

Other Agreements (Tables)

Other Agreements (Tables)	9 Months Ended
	Sep. 30, 2020
Other Agreements [Abstract]
Schedule of Remaining Minimum Principal Payments Due	Remaining minimum payments to be made in 2020 include $6,626 of revenue-based payments payable as of September 30, 2020 and the fourth quarter 2020 minimum payment. Minimum payments to be made in 2021 include an estimate of additional revenue-based payments to be made in the first, second and third quarters of 2021 relating to revenue generated in the fourth quarter of 2020 and in the first and second quarters of 2021, estimated using revenue generated in the same quarters in 2019 and 2020. Minimum payments for the remaining periods include only the minimum quarterly payments to be made in each period. Actual payments could vary from what is shown in the table, to the extent that 6% of the Company’s annual revenue in 2021 and beyond exceeds $400,000. The remaining minimum payments to be made to NuvoGen as of September 30, 2020 are as follows for each fiscal year: 2020 $ 106,626 2021 639,323 2022 400,000 2023 400,000 2024 400,000 2025 and beyond 3,073,428 Total NuvoGen obligation payments 5,019,377 Plus interest accretion 82,540 Total NuvoGen obligation, net $ 5,101,917

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Outstanding Options, Warrants, Restricted Stock Units and Debt Conversion Option Excluded from Computation of Diluted Net Loss per Share	The following outstanding options, warrants, restricted stock units and debt conversion option were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2020 2019 Options to purchase common stock 7,485,489 2,940,990 Common stock warrants 880,328 236,915 Restricted stock units 204,051 247,079 QNAH convertible note - 794,665

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2020
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Outstanding Warrants	The following table shows the common stock warrants outstanding as of September 30, 2020: Warrant Issuance Date Shares of Common Exercise Price/Share Expiration Date August 2014 28,713 $ 23.51 2024 December 2014 144,772 14.00 2022 March 2016 45,307 2.76 2026 March 2018 18,123 7.73 2028 September 2019 2,234,925 0.01 N/A June 2020 643,413 0.7771 2030

Stockholders Deficit (Tables)

Stockholders Deficit (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Summary of Stock Option Plans Activity	A summary of the Company’s stock option activity for the nine months ended September 30, 2020 is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2019 2,904,898 $ 2.37 8.0 $ 781 Granted 5,766,000 0.52 Exercised - - $ - Forfeited (1,102,897 ) 1.01 Expired/Cancelled (82,512 ) 3.29 Balance at September 30, 2020 7,485,489 $ 1.13 8.9 $ 404 Exercisable at September 30, 2020 2,489,579 $ 1.98 7.4 $ 101
Summary of Restricted Stock Unit ("RSU") Award Activity	The following table summarizes restricted stock unit (“RSU”) award activity for the nine months ended September 30, 2020: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2019 223,745 $ 2.91 Granted 105,000 0.52 Released (97,819 ) 2.43 Forfeited (26,875 ) 2.75 Balance at September 30, 2020 204,051 $ 1.94 Vested and unissued at September 30, 2020 20,783 $ 2.21
Summary of Stock-Based Compensation Recorded in the Condensed Consolidated Statements of Operations	Stock-based compensation expense recorded in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Selling, general and administrative $ 380,676 $ 226,645 $ 1,070,651 $ 625,821 Research and development 884 74,652 81,374 181,336 Cost of product and product-related services revenue 5,389 15,258 11,717 37,976 $ 386,949 $ 316,555 $ 1,163,742 $ 845,133

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Summary of Components of Lease Cost	The components of lease cost for operating leases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Operating leases Operating lease cost $ 182,287 $ 174,581 $ 570,163 $ 435,312 Variable lease cost 36,554 36,210 89,716 89,468 Operating lease expense 218,841 210,791 659,879 524,780 Short-term lease rent expense — — — 1,497 Total rent expense $ 218,841 $ 210,791 $ 659,879 $ 526,277 The components of lease cost for financing leases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Financing leases Amortization of right-of-use assets $ 10,035 $ 10,128 $ 34,033 $ 36,908 Interest on lease liability 2,092 1,559 7,074 5,528 Total financing lease cost $ 12,127 $ 11,687 $ 41,107 $ 42,436
Summary of Other Information Related to Operating Leases	The table below summarizes other information related to the Company’s operating leases: Nine Months Ended September 30, 2020 2019 Operating cash flows for operating leases $ 665,095 $ 550,024 Establishment of operating lease liabilities arising from obtaining right-of-use assets $ 21,078 $ 2,038,193 Weighted-average remaining lease term – operating leases 1.9 2.4 Weighted-average discount rate – operating leases 9.6 % 9.6 %
Summary of Remaining Maturities of Operating Leases, Excluding Short-term Leases	As of September 30, 2020, remaining maturities of our operating leases, excluding short-term leases, are as follows: 2020 $ 218,157 2021 340,970 2022 281,232 2023 70,848 Total 911,207 Less present value discount (84,311 ) Operating lease liabilities, net $ 826,896
Summary of Other Information Related to Financing Leases	The table below summarizes other information related to the Company’s financing leases: Nine Months Ended September 30, 2020 2019 Weighted-average remaining lease term – financing leases 3.5 2.0 Weighted-average discount rate – financing leases 9.77 % 9.77 %
Summary of Remaining Maturities of Financing Leases	As of September 30, 2020, remaining maturities of our financing leases are as follows: 2020 $ 10,445 2021 28,355 2022 20,716 2023 18,396 2024 16,080 Total 93,992 Less present value discount (14,737 ) Financing lease liabilities, net $ 79,255

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Summary of Product Warranty Liability	The following is a summary of the Company’s general product warranty liability, which is included in accrued liabilities in the accompanying condensed consolidated balance sheets as of the dates indicated. Expense relating to the recording of this reserve is recorded in cost of product and product-related services revenue within the accompanying condensed consolidated statements of operations. Nine Months Ended September 30, 2020 2019 Beginning balance $ 94,482 $ 63,461 Cost of warranty claims (19,310 ) (38,691 ) Increase in warranty reserve 12,423 64,637 Ending balance $ 87,595 $ 89,407

Description of Business, Basi_2

Description of Business, Basis of Presentation and Principles of Consolidation - Additional Information (Details)	Mar. 27, 2020	Sep. 30, 2020USD ($)Customer	Sep. 30, 2019Customer	Sep. 30, 2020USD ($)SegmentCustomer	Sep. 30, 2019Customer	Dec. 31, 2019USD ($)Customer
Significant Accounting Policies [Line Items]
Number of operating segments | Segment				1
CARES Act of 2020 percentage of NOL carryovers and carrybacks offsetting taxable income	100.00%
CARES act of 2020, net operating loss carryback period	5 years
Accumulated deficit | $		$ (186,897,880)		$ (186,897,880)		$ (170,317,643)
Working capital | $		28,400,000		28,400,000
Long-term liabilities | $		$ 14,500,000		$ 14,500,000
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer		2	2	2	3
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage		19.00%	29.00%	31.00%	31.00%
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage		24.00%	39.00%	16.00%	23.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage		10.00%	20.00%	10.00%	22.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage					21.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer				2		2
Number of additional customers | Customer				2
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage				30.00%		29.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage				13.00%		25.00%
Accounts Receivable | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage				11.00%
Accounts Receivable | Customer Concentration Risk | Customer Four
Significant Accounting Policies [Line Items]
Sales revenue percentage				11.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 18,884,468	$ 7,619,748	$ 34,847,086
Restricted cash - non-current			3,270,247
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$ 18,884,468		$ 38,117,333

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2017	Sep. 30, 2020
ASU 2018-13
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted		true
Change in accounting principle, accounting standards update, adoption date		Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect		true
ASU 2018-18
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted		true
Change in accounting principle, accounting standards update, adoption date		Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect		true
NuvoGen Asset Purchase Agreement
Significant Accounting Policies [Line Items]
Convertible debt, fair value		$ 4.5
QIAGEN North American Holdings, Inc. | Convertible Promissory Note
Significant Accounting Policies [Line Items]
Gross proceeds from issuance of subordinated notes	$ 3

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,130,443	$ 872,947
Work in process	165,447	151,351
Finished goods	270,433	284,772
Total gross inventory	1,566,323	1,309,070
Less inventory allowance	(27,770)	(39,403)
Inventory, net	$ 1,538,553	$ 1,269,667

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Inventory [Line Items]
Provision for excess inventory	$ 10,530	$ 81,582	$ 12,202	$ 126,582
Finished goods inventory	270,433		270,433		$ 284,772
HTG EdgeSeq
Inventory [Line Items]
Finished goods inventory	$ 104,950		$ 104,950		$ 79,338

Fair Value Instruments - Financ

Fair Value Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Asset included in:
Investments available-for-sale at fair value	$ 11,632,160	$ 25,410,222
U.S. Treasury Securities
Asset included in:
Investments available-for-sale at fair value	3,238,088	5,961,983
Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	8,394,072	19,448,239
Fair Value, Measurements, Recurring
Asset included in:
Financial Assets	30,436,011	32,627,318
Fair Value, Measurements, Recurring | Money Market Securities
Asset included in:
Cash and cash equivalents	18,803,851	7,217,096
Fair Value, Measurements, Recurring | U.S. Treasury Securities
Asset included in:
Investments available-for-sale at fair value	3,238,088	5,961,983
Fair Value, Measurements, Recurring | Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	8,394,072	19,448,239
Fair Value, Measurements, Recurring | Level 1
Asset included in:
Financial Assets	22,041,939	13,179,079
Fair Value, Measurements, Recurring | Level 1 | Money Market Securities
Asset included in:
Cash and cash equivalents	18,803,851	7,217,096
Fair Value, Measurements, Recurring | Level 1 | U.S. Treasury Securities
Asset included in:
Investments available-for-sale at fair value	3,238,088	5,961,983
Fair Value, Measurements, Recurring | Level 2
Asset included in:
Financial Assets	8,394,072	19,448,239
Fair Value, Measurements, Recurring | Level 2 | Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	$ 8,394,072	$ 19,448,239

Fair Value Instruments - Additi

Fair Value Instruments - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0	$ 0

Available-for-Sale Securities -

Available-for-Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 11,628,109	$ 25,410,463
Gross Unrealized Gains	4,051	394
Gross Unrealized Losses	0	(635)
Fair Value (Net Carrying Amount)	11,632,160	25,410,222
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	8,394,072	19,448,239
Fair Value (Net Carrying Amount)	8,394,072	19,448,239
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	3,234,037	5,962,224
Gross Unrealized Gains	4,051	394
Gross Unrealized Losses		(635)
Fair Value (Net Carrying Amount)	$ 3,238,088	$ 5,961,983

Available-for-Sale Securities_2

Available-for-Sale Securities - Additional Information (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Available-for-sale securities investments, gross unrealized losses	$ 0						$ 0		$ 635
Unrealized gain (losses) on short and long-term investments	$ (17,501)	$ (26,136)	$ 47,697	$ (1,864)	$ 819	$ 3,353	4,060	$ 2,308
Other-than-temporary impairment							$ 0

Available-for-Sale Securities_3

Available-for-Sale Securities - Summary of Contractual Maturities of Debt Investment Securities (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	$ 11,632,160
Fair Value (Net Carrying Amount)	11,632,160	$ 25,410,222
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	3,238,088
Fair Value (Net Carrying Amount)	3,238,088	5,961,983
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	8,394,072
Fair Value (Net Carrying Amount)	$ 8,394,072	$ 19,448,239

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Furniture & fixtures	$ 1,082,717	$ 1,089,371
Leasehold improvements	1,943,534	1,987,997
Equipment used in manufacturing	2,225,122	2,305,340
Equipment used in research & development	2,473,854	2,134,019
Equipment used in the field	208,005	182,762
Software	418,251	374,812
Property and equipment	8,351,483	8,074,301
Less: accumulated depreciation and amortization	(6,824,785)	(5,834,168)
Property and equipment, net	$ 1,526,698	$ 2,240,133

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 300,000	$ 300,000	$ 1,039,989	$ 920,863

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued employee bonuses	$ 331,642	$ 900,740
Payroll and employee benefit accruals	643,730	469,530
Accrued professional fees	102,551	43,850
Accrued interest	55,691	245,350
Accrued rebate	60,694
Other accrued liabilities	192,517	210,826
Total accrued liabilities	$ 1,386,825	$ 1,870,296

Debt Obligations - Schedule of

Debt Obligations - Schedule of Current Portion of Long Term Debt, Net (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Convertible note, net of debt issuance costs		$ 2,987,667
Insurance Note Payable	$ 410,894
Current portion of long-term debt, net	2,266,884	$ 2,987,667
SVB Term Loan
Debt Instrument [Line Items]
SVB Term Loan payable, net of discount and debt issuance costs	1,000,000
PPP Loan
Debt Instrument [Line Items]
PPP Loan	$ 855,990

Debt Obligations - Schedule o_2

Debt Obligations - Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Long term debt non current	$ 9,446,985	$ 6,871,545
SVB Term Loan
Debt Instrument [Line Items]
Loan payable, net of discount and debt issuance costs	8,585,975
PPP Loan
Debt Instrument [Line Items]
PPP Loan	$ 861,010
MidCap Credit Facility
Debt Instrument [Line Items]
Loan payable, net of discount and debt issuance costs		$ 6,871,545

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details) - USD ($)	Jun. 25, 2020	Jun. 24, 2020	Apr. 27, 2020	Apr. 21, 2020	Feb. 26, 2020	Oct. 31, 2017	Sep. 30, 2020	Sep. 30, 2020
Debt Instrument [Line Items]
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note								$ (522,394)
Proceeds from Paycheck Protection Program Loan								$ 1,717,000
Insurance Note
Debt Instrument [Line Items]
Debt instrument, interest rate			3.61%
Loan repayment start date			Jun. 6, 2020
Loan term			9 months
Loan prepayment penalties			$ 0
Down payment on insurance note			200,000
Premium payable on insurance note			$ 700,000
SVB Term Loan
Debt Instrument [Line Items]
Debt instrument, principal amount		$ 10,000,000
Debt instrument, interest rate		5.75%
Extend the interest-only payments		6 months
Loan maturity date		Dec. 1, 2023
Debt instrument early termination fee percentage		3.00%
Debt instrument second anniversary early termination fee percentage		2.00%
Debt instrument after second anniversary early termination fee percentage		1.00%
Debt instrument final payment percentage		8.00%
Debt instrument, covenants unrestricted cash		$ 12,500,000
Debt instrument increase in interest on obligation percentage		5.00%
Warrant to purchase common stock, shares		643,413
Warrant purchase price		$ 0.7771					$ 0.7771	$ 0.7771
Warrant expiration date		Jun. 24, 2030
Fair value of warrants		$ 400,000
Debt instrument, amortization expense							$ 100,000	$ 100,000
Debt discount, fees and debt issuance costs							1,214,025	$ 1,214,025
SVB Term Loan | Prime Rate | Minimum
Debt Instrument [Line Items]
Debt instrument, interest at floating rate		2.50%
Paycheck Protection Program Loan
Debt Instrument [Line Items]
Debt instrument, interest rate				1.00%
Loan maturity date				Apr. 21, 2022
Loan repayment start date				Mar. 21, 2021
Loan term				14 months
Loan prepayment penalties				$ 0
Payroll compensation cost maximum exemption limit				100,000
Paycheck Protection Program Loan | Silicon Valley Bank
Debt Instrument [Line Items]
Proceeds from Paycheck Protection Program Loan				$ 1,717,000
Paycheck Protection Program Loan | Minimum
Debt Instrument [Line Items]
Annual salary reduction rate				25.00%
Paycheck Protection Program Loan | Maximum
Debt Instrument [Line Items]
Percentage of non-payroll costs forgiven				40.00%
Salaries and wages				$ 100,000
Convertible Promissory Note | QIAGEN North American Holdings, Inc.
Debt Instrument [Line Items]
Cash proceeds from issuance of subordinated notes						$ 3,000,000
Repayments of aggregate amount	$ 3,200,000
MidCap Credit Facility
Debt Instrument [Line Items]
Debt instrument interest only payment period					11 months
Debt Instrument, Frequency of Periodic Payment								25 equal monthly installments
Debt instrument interest only payment period if revenue milestone achieved					4 months
Debt instrument frequency of periodic payment if revenue milestone achieved								21 equal monthly installments
Repayment of outstanding principal and interest	$ 7,500,000							$ 7,438,623
MidCap Credit Facility | QIAGEN North American Holdings, Inc.
Debt Instrument [Line Items]
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note								500,000
Unamortized discounts							$ 300,000	$ 300,000

Debt Obligations - Schedule o_3

Debt Obligations - Schedule of Remaining Principal Repayments due Under SVB Term Loan (Details) - SVB Term Loan	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
2021	$ 2,000,000
2022	4,000,000
2023	4,000,000
Total SVB Term Loan payments	10,000,000
Less discount and deferred financing costs	(1,214,025)
Plus final fee premium	800,000
Total SVB Term Loan, net	$ 9,585,975

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Product and Product-Related Service Revenue from Sale of Instruments and Consumables (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 1,777,098	$ 5,404,793	$ 5,965,866	$ 14,403,938
Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	1,701,068	4,311,043	5,417,731	11,397,916
HTG EdgeSeq | Instruments
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	71,742	414,491	563,396	1,100,606
HTG EdgeSeq | Consumables
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	764,605	1,058,386	2,091,848	2,218,674
HTG EdgeSeq | Product revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	836,347	1,472,877	2,655,244	3,319,280
HTG EdgeSeq | Custom RUO assay design
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	238,502	2,129,251	1,210,968	3,978,428
HTG EdgeSeq | RUO Sample processing
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	626,219	708,915	1,551,519	4,100,208
HTG EdgeSeq | Product-related services revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	864,721	2,838,166	2,762,487	8,078,636
HTG EdgeSeq | Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 1,701,068	$ 4,311,043	$ 5,417,731	$ 11,397,916

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Agreements for product and product-related services revenue, description			The Company’s agreements for product and product-related services revenue have an expected duration of one year or less
Revenue recognized			$ 946,452	$ 1,109,443
Service revenue	$ 1,777,098	$ 5,404,793	5,965,866	14,403,938
Profit sharing payments	940,892	2,939,007	2,931,026	7,492,905
Accounts receivable	1,370,201		1,370,201		$ 3,164,176
Research and development	1,255,416	2,570,355	4,914,467	7,898,742
Contract assets	42,000		42,000		0
Contract liabilities	524,756	563,628	524,756	563,628	599,454	$ 410,947
SOW Two
Disaggregation Of Revenue [Line Items]
Accounts receivable	100,000		100,000		200,000
Research and development		200,000	400,000	1,300,000
SOW Three
Disaggregation Of Revenue [Line Items]
Accounts receivable	0		0		$ 800,000
Research and development		300,000		600,000
Custom RUO Assay Design and Related Agreements
Disaggregation Of Revenue [Line Items]
Revenue recognized	0	0	0	41,137
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Service revenue	76,030	1,093,750	548,135	3,006,022
Collaborative Development Services | SOW Two
Disaggregation Of Revenue [Line Items]
Service revenue	100,000	600,000	500,000	2,200,000
Profit sharing payments	100,000	300,000	100,000	400,000
Collaborative Development Services | SOW Three
Disaggregation Of Revenue [Line Items]
Service revenue	0	$ 500,000	$ 0	$ 800,000
Minimum
Disaggregation Of Revenue [Line Items]
Customer payment term			30 days
Maximum
Disaggregation Of Revenue [Line Items]
Customer payment term			90 days
Maximum | SOW Two
Disaggregation Of Revenue [Line Items]
Research and development	$ 100,000
Maximum | QIAGEN Manchester Limited
Disaggregation Of Revenue [Line Items]
Term of agreement			1 year

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Additional Information1 (Details) $ in Millions	Sep. 30, 2020USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-10-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Deferred revenue to be realized	$ 0.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-10-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Deferred revenue to be realized	$ 0.2

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Schedule of Collaborative Development Services (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation Of Revenue [Line Items]
Service revenue	$ 1,777,098	$ 5,404,793	$ 5,965,866	$ 14,403,938
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Service revenue	$ 76,030	$ 1,093,750	$ 548,135	$ 3,006,022

Revenue from Contracts with C_7

Revenue from Contracts with Customers - Schedule of Changes in Contract Liability (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Disaggregation Of Revenue [Line Items]
Beginning Balance	$ 599,454	$ 410,947
Deferral of revenue	871,754	1,262,124
Recognition of deferred revenue	(946,452)	(1,109,443)
Ending Balance	524,756	563,628
Product Revenue
Disaggregation Of Revenue [Line Items]
Beginning Balance	95,148	116,547
Deferral of revenue	335,265	126,425
Recognition of deferred revenue	(325,181)	(172,610)
Ending Balance	105,232	70,362
Custom RUO Assay Design
Disaggregation Of Revenue [Line Items]
Beginning Balance	66,216	50,000
Deferral of revenue	459,385	671,885
Recognition of deferred revenue	(525,601)	(707,641)
Ending Balance		14,244
Sample Processing
Disaggregation Of Revenue [Line Items]
Beginning Balance	438,090	244,400
Deferral of revenue	77,104	463,814
Recognition of deferred revenue	(95,670)	(229,192)
Ending Balance	$ 419,524	$ 479,022

Other Agreements - Additional I

Other Agreements - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Other Agreements [Line Items]
Accretion expense			$ (9,771)	$ (10,273)
Measurement Input, Default Rate
Other Agreements [Line Items]
Discount rate used to calculate asset purchase obligation	2.5		2.5
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due from beginning 2019	$ 400,000		$ 400,000
Percentage on annual revenues for cash consideration to be paid			6.00%
Asset purchase agreement fixed quarterly payments	100,000		$ 100,000
Additional revenue based payments payable					$ 200,000
NuvoGen Asset Purchase Agreement | Maximum
Other Agreements [Line Items]
Additional revenue based payments payable	100,000		100,000
NuvoGen
Other Agreements [Line Items]
Convertible notes and related debt discount	(82,540)		(82,540)		$ (92,311)
Accretion expense	$ (3,115)	$ (3,790)	$ (9,771)	$ (10,273)

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Minimum Principal Payments Due (Details) - NuvoGen Asset Purchase Agreement	Sep. 30, 2020USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2020	$ 106,626
2021	639,323
2022	400,000
2023	400,000
2024	400,000
2025 and beyond	3,073,428
Total NuvoGen obligation payments	5,019,377
Plus interest accretion	82,540
Total NuvoGen obligation, net	$ 5,101,917

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019
Class Of Warrant Or Right [Line Items]
Proceeds from exercise of pre-funded warrants			$ 31,768
Pre-funded Warrants
Class Of Warrant Or Right [Line Items]
Exercise price of warrants			$ 0.01
Private Placement | Institutional Accredited Investors
Class Of Warrant Or Right [Line Items]
Exercise price of warrants			$ 0.65	$ 0.65
Private Placement | Institutional Accredited Investors | Pre-funded Warrants
Class Of Warrant Or Right [Line Items]
Issuance of warrants, shares			5,411,687	5,411,687
Number of securities called by warrants			5,411,687	5,411,687
Exercise price of warrants			$ 0.64	$ 0.64
Exercise price of warrants, exercisable subject to beneficial ownership limitations			$ 0.01	$ 0.01
Warrants exercised	3,176,762	3,176,762
Proceeds from exercise of pre-funded warrants	$ 31,768	$ 31,768
Unexercised warrants outstanding			2,234,925

Net Loss per Share - Outstandin

Net Loss per Share - Outstanding Options, Warrants, Restricted Stock Units and Debt Conversion Option Excluded from Computation of Diluted Net Loss per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	7,485,489	2,940,990
Restricted Stock Units R S U
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	204,051	247,079
Warrants | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	880,328	236,915
QNAH convertible note
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share		794,665

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Sep. 30, 2020	Jun. 24, 2020	Sep. 30, 2019
Class Of Warrant Or Right [Line Items]
Proceeds from exercise of pre-funded warrants			$ 31,768
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants				643,413
Exercise price of warrants			$ 0.7771	$ 0.7771
Warrant to purchase common stock			643,413
Warrant expire date			Jun. 24, 2030
Pre-funded Warrants
Class Of Warrant Or Right [Line Items]
Exercise price of warrants			$ 0.01
Warrant to purchase common stock			2,234,925
Minimum | SVB Term Loan
Class Of Warrant Or Right [Line Items]
Warrant to purchase common stock			643,413
Private Placement | Institutional Accredited Investors
Class Of Warrant Or Right [Line Items]
Exercise price of warrants			$ 0.65		$ 0.65
Private Placement | Institutional Accredited Investors | Pre-funded Warrants
Class Of Warrant Or Right [Line Items]
Issuance of warrants, shares			5,411,687		5,411,687
Number of securities called by warrants			5,411,687		5,411,687
Exercise price of warrants			$ 0.64		$ 0.64
Exercise price of warrants, exercisable subject to beneficial ownership limitations			$ 0.01		$ 0.01
Proceeds from exercise of pre-funded warrants	$ 31,768	$ 31,768
Warrants exercised	3,176,762	3,176,762

Warrants -Summary of Outstandin

Warrants -Summary of Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Jun. 24, 2020
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2020-06
Shares of Common Stock Underlying Warrants	643,413
Exercise Price/Share	$ 0.7771	$ 0.7771
Expiration Date	2030
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2014-12
Shares of Common Stock Underlying Warrants	144,772
Exercise Price/Share	$ 14
Expiration Date	2022
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2016-03
Shares of Common Stock Underlying Warrants	45,307
Exercise Price/Share	$ 2.76
Expiration Date	2026
Common Stock Tranche one
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2018-03
Shares of Common Stock Underlying Warrants	18,123
Exercise Price/Share	$ 7.73
Expiration Date	2028
Pre-funded Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2019-09
Shares of Common Stock Underlying Warrants	2,234,925
Exercise Price/Share	$ 0.01
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2014-08
Shares of Common Stock Underlying Warrants	28,713
Exercise Price/Share	$ 23.51
Expiration Date	2024

Stockholders Deficit - Addition

Stockholders Deficit - Additional Information (Details) - USD ($)	Mar. 24, 2020	Feb. 25, 2020	Jan. 01, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Aug. 31, 2020	Dec. 31, 2019	Nov. 30, 2019	May 31, 2019	May 31, 2015
Class Of Stock [Line Items]
Common stock, shares outstanding							71,078,958				71,078,958			58,090,233
Common stock, shares issued							71,078,958				71,078,958			58,090,233
Employee Stock Option
Class Of Stock [Line Items]
Unrecognized compensation expense							$ 2,700,000				$ 2,700,000
Compensation expense period expected to be recognized											2 years 5 months 8 days
Restricted Stock Units R S U
Class Of Stock [Line Items]
Unrecognized compensation expense							$ 300,000				$ 300,000
Compensation expense period expected to be recognized											1 year 11 months 4 days
Vested and unissued RSU awards, description											Vested and unissued awards at September 30, 2020 represents RSU awards for which the vesting date was September 30, 2020, but for which issuance of the awards occurred in October 2020.
Vested and unissued RSU awards vesting date											Sep. 30, 2020
Vested and unissued RSU awards issuance date											Oct. 31, 2020
2014 Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for issuance													1,028,292			200,000	940,112
Number of shares available for issuance													0			0	0
Number of additional shares registered for issuance			2,323,609
2020 Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for issuance													11,170,288
Options granted in term											10 years
2020 Equity Incentive Plan | Board of Directors | Minimum
Class Of Stock [Line Items]
Options exercise period											1 year
2020 Equity Incentive Plan | Board of Directors | Maximum
Class Of Stock [Line Items]
Options exercise period											4 years
Common Stock
Class Of Stock [Line Items]
Number of shares issued upon the conversion								2,750,000
Cantor Sales Agreement
Class Of Stock [Line Items]
Common stock price per share															$ 0.001
Exchange Agreement
Class Of Stock [Line Items]
Common stock, shares outstanding		4,110,000
Conversion of convertible preferred stock into common stock		100
Exchange Agreement | Series A Convertible Preferred Stock
Class Of Stock [Line Items]
Issuance of common stock, shares		10,170
Preferred stock, shares issued		41,100
Preferred stock, par value		$ 0.001
Issuance of common stock		$ 600,030
Stock issued, price per share		$ 59
Preferred stock, shares converted				27,500
Preferred stock, shares outstanding							23,770				23,770
Exchange Agreement | Common Stock
Class Of Stock [Line Items]
Number of shares issued upon the conversion				2,750,000
LP Purchase Agreement | Common Stock
Class Of Stock [Line Items]
Issuance of common stock, shares									615,384
Issuance of common stock									$ 615
Pre-funded Warrants
Class Of Stock [Line Items]
Exercise price of warrants							$ 0.01				$ 0.01
Lincoln Park | LP Purchase Agreement
Class Of Stock [Line Items]
Common stock value right to sell, maximum	$ 20,000,000
Agreement term	36 months
Common stock, shares issued	615,384						0				0
Lincoln Park | LP Purchase Agreement | Additional Paid-In-Capital
Class Of Stock [Line Items]
Commitment consideration and related transaction costs										$ 0	$ 100,000	$ 0
Private Placement | Institutional Accredited Investors
Class Of Stock [Line Items]
Exercise price of warrants						$ 0.65	$ 0.65			$ 0.65	$ 0.65	$ 0.65
Private Placement | Institutional Accredited Investors | Pre-funded Warrants
Class Of Stock [Line Items]
Issuance of warrants, shares						5,411,687	5,411,687			5,411,687	5,411,687	5,411,687
Number of securities called by warrants						5,411,687	5,411,687			5,411,687	5,411,687	5,411,687
Exercise price of warrants						$ 0.64	$ 0.64			$ 0.64	$ 0.64	$ 0.64
Exercise price of warrants, exercisable subject to beneficial ownership limitations						$ 0.01	$ 0.01			$ 0.01	$ 0.01	$ 0.01
Private Placement | Cantor Fitzgerald & Co. | Pre-funded Warrants
Class Of Stock [Line Items]
Number of securities called by warrants					3,176,762				3,176,762
Agent cash fee, percentage of gross proceeds from sale of warrants						6.00%
Net proceeds from sale of warrants					$ 31,768	$ 3,100,000
ATM Offering
Class Of Stock [Line Items]
Gross proceeds from issuance of common stock											$ 6,700,000
Payment of sales commissions											200,000
Net proceeds from issuance of common stock from the ATM Offering											$ 6,400,000
Issuance of common stock							$ 2,557,012	$ 1,395,058	$ 2,435,912
ATM Offering | Common Stock
Class Of Stock [Line Items]
Issuance of common stock, shares							3,952,240	2,084,714	4,399,062		10,436,016
Deferred offering costs														$ 100,000
Issuance of common stock							$ 3,952	$ 2,085	$ 4,399

Stockholders Deficit - Summary

Stockholders Deficit - Summary of Stock Option Plans Activity (Details) - Employee Stock Option - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance	2,904,898
Number of Shares, Granted	5,766,000
Number of Shares, Forfeited	(1,102,897)
Number of Shares, Expired/Cancelled	(82,512)
Number of Shares, Ending Balance	7,485,489	2,904,898
Number of Shares, Exercisable	2,489,579
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 2.37
Weighted-Average Exercise Price Per Share, Granted	0.52
Weighted-Average Exercise Price Per Share, Forfeited	1.01
Weighted-Average Exercise Price Per Share, Expired/Cancelled	3.29
Weighted-Average Exercise Price Per Share, Ending Balance	1.13	$ 2.37
Weighted-Average Exercise Price Per Share, Exercisable	$ 1.98
Weighted-Average Remaining Contractual Life, Outstanding	8 years 10 months 25 days	8 years
Weighted-Average Remaining Contractual Life, Exercisable	7 years 4 months 24 days
Aggregate Intrinsic Value, Balance	$ 404	$ 781
Aggregate Intrinsic Value, Exercisable	$ 101

Stockholders Deficit - Summar_2

Stockholders Deficit - Summary of Restricted Stock Unit ('RSU') Award Activity (Details) - Restricted Stock Units R S U	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Restricted Stock Units (RSU)
Beginning Balance | shares	223,745
Granted | shares	105,000
Released | shares	(97,819)
Forfeited | shares	(26,875)
Ending Balance | shares	204,051
Vested and unissued at September 30, 2020 | shares	20,783
Weighted Average Grant Date Fair Value Per Share
Beginning Balance | $ / shares	$ 2.91
Granted | $ / shares	0.52
Released | $ / shares	2.43
Forfeited | $ / shares	2.75
Ending Balance | $ / shares	1.94
Vested and unissued at September 30, 2020 | $ / shares	$ 2.21

Stockholders Deficit - Summar_3

Stockholders Deficit - Summary of Stock-Based Compensation Recorded in the Condensed Consolidated Statements of Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 386,949	$ 316,555	$ 1,163,742	$ 845,133
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	380,676	226,645	1,070,651	625,821
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	884	74,652	81,374	181,336
Cost of Product and Product-related Services Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 5,389	$ 15,258	$ 11,717	$ 37,976

Leases - Additional Information

Leases - Additional Information (Details)	9 Months Ended
	Sep. 30, 2020USD ($)
Lessee Lease Description [Line Items]
Lease expiration year	2023
Operating lease, description	The Company’s most significant active leases as of September 30, 2020 are for office and manufacturing space in Tucson, Arizona
Financing lease liabilities, net of discount	$ 79,255
Financing lease liabilities, current	$ 26,620
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent
Financing lease liabilities, non current	$ 52,635
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesNoncurrent
Financing leases, right-of-use assets	$ 75,563
Tucson, Arizona
Lessee Lease Description [Line Items]
Lease expiration year	2021
San Carlos, California
Lessee Lease Description [Line Items]
Lease expiration year	2023

Leases - Summary of Components

Leases - Summary of Components of Lease Cost for Operating Leases (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 182,287	$ 174,581	$ 570,163	$ 435,312
Variable lease cost	36,554	36,210	89,716	89,468
Operating lease expense	218,841	210,791	659,879	524,780
Short-term lease rent expense				1,497
Total rent expense	$ 218,841	$ 210,791	$ 659,879	$ 526,277

Leases - Summary of Other Infor

Leases - Summary of Other Information Related to Operating Leases (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating cash flows for operating leases	$ 665,095	$ 550,024
Establishment of operating lease liabilities arising from obtaining right-of-use assets	$ 21,078	$ 2,038,193
Weighted-average remaining lease term – operating leases	1 year 10 months 24 days	2 years 4 months 24 days
Weighted-average discount rate – operating leases	9.60%	9.60%

Leases - Summary of Remaining M

Leases - Summary of Remaining Maturities of Operating Leases, Excluding Short-term Leases (Details)	Sep. 30, 2020USD ($)
Leases [Abstract]
2020	$ 218,157
2021	340,970
2022	281,232
2023	70,848
Total	911,207
Less present value discount	(84,311)
Operating lease liabilities, net	$ 826,896

Leases - Summary of Component_2

Leases - Summary of Components of Lease Cost for Financing Leases (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Amortization of right-of-use assets	$ 10,035	$ 10,128	$ 34,033	$ 36,908
Interest on lease liability	2,092	1,559	7,074	5,528
Total financing lease cost	$ 12,127	$ 11,687	$ 41,107	$ 42,436

Leases - Summary of Other Inf_2

Leases - Summary of Other Information Related to Financing Leases (Details)	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Weighted-average remaining lease term – financing leases	3 years 6 months	2 years
Weighted-average discount rate – financing leases	9.77%	9.77%

Leases - Summary of Remaining_2

Leases - Summary of Remaining Maturities of Financing Leases (Details)	Sep. 30, 2020USD ($)
Leases [Abstract]
2020	$ 10,445
2021	28,355
2022	20,716
2023	18,396
2024	16,080
Total	93,992
Less present value discount	(14,737)
Financing lease liabilities, net	$ 79,255

Commitments and Contingencies -

Commitments and Contingencies - Summary Of Product Warranty Liability (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 94,482	$ 63,461
Cost of warranty claims	(19,310)	(38,691)
Increase in warranty reserve	12,423	64,637
Ending balance	$ 87,595	$ 89,407